Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Heron Therapeutics, Inc. (HRTX)
USD0.44
+0.01 (+2.12%)
US NASDAQ Healthcare Biotechnology
Address
4242 Campus Point Court 92121
Cary, CA, US
Cary, CA, US
CEO
Craig Alexander Collard
Website
herontx.com
IPO
1987-08-26
CIK 818033 ISIN US4277461020
Also trades on
London Stock Exchange · 0J4V.L (USD)
NASDAQ Capital Market · HRTX (USD)
Description
Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled release of various short-acting pharmacological agents. This technology ensures therapeutic concentrations are maintained for periods ranging from days to weeks following just a single administration. Among its commercialized products is SUSTOL (granisetron), an extended-release injectable designed to prevent both immediate and delayed nausea and vomiting triggered by moderately emetogenic chemotherapy, or specific anthracycline and cyclophosphamide combination therapies. Additionally, Heron markets CINVANTI, an intravenous formulation of aprepitant. CINVANTI, which acts as a substance P/neurokinin-1 receptor antagonist, is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients undergoing highly or moderately emetogenic cancer chemotherapy. The company's development pipeline includes ZYNRELEF, an innovative dual-acting local anesthetic that combines bupivacaine, a local anesthetic, with a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam in a single fixed-dose formulation. Also in development is HTX-019, an experimental therapy aimed at preventing postoperative nausea and vomiting (PONV). Furthermore, HTX-034 is being advanced for postoperative pain management and is currently undergoing Phase Ib/II clinical trials, notably in patients recovering from bunionectomy procedures. Originally established in 1983 as A.P. Pharma, Inc., the company adopted its current name, Heron Therapeutics, Inc., in January 2014. Its corporate headquarters are situated in San Diego, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.44
+0.01 (+2.12%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
1.57
Float Shares
132.12M
Free Float %
83.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.93% | -25.83% | +13.04% | -16.16% | -13.14% | -25.83% | -52.97% | -31.13% | -94.46% | -94.12% | -99.83% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (19 ratings, all time)
Buy
Price Targets & DCF
Current price
0.44
Low
5.00
+1,039.0%
Consensus
6.67
+1,419.4%
Median
6.00
+1,266.7%
High
9.00
+1,950.1%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 1 |
6.00
+1,266.7%
|
| All Time | 3 |
6.67
+1,419.4%
|
Quality scores
Altman Z-Score
-9.61
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+7.4% ★ Q1'26: -10.8% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-34.7% Q1'26: -300.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-32.3% Q1'26: -5.6% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-13.0% Q1'26: -13.7% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-18.6% Q1'26: -18.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+9.4% Q1'26: +23.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-7.87× Q1'26: -7.43× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 2 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.28M
est: 1.09M (+17.6%)
|
30.77M
est: 30.08M (+2.3%)
|
77.47M
est: 75.72M (+2.3%)
|
145.97M
est: 141.94M (+2.8%)
|
88.64M
est: 87.61M (+1.2%)
|
86.35M
est: 91.84M (-6.0%)
|
107.67M
est: 104.90M (+2.6%)
|
127.04M
est: 136.36M (-6.8%)
|
144.29M
est: 140.89M (+2.4%)
|
154.90M
est: 154.24M (+0.4%)
|
173.15M
170.88M – 175.42M
+12.3% YoY
|
196.63M
191.09M – 202.46M
+13.6% YoY
|
222.69M
222.68M – 222.69M
+13.3% YoY
|
263.10M
255.69M – 270.89M
+18.1% YoY
|
295.25M
286.93M – 303.99M
+12.2% YoY
|
| EBITDA |
-169.38M
est: -156.74M (-8.1%)
|
-192.02M
est: -173.91M (-10.4%)
|
-174.66M
est: -167.57M (-4.2%)
|
-201.23M
est: -109.35M (-84.0%)
|
-222.53M
est: -229.50M (+3.0%)
|
-215.25M
est: -227.73M (+5.5%)
|
-176.66M
est: -224.96M (+21.5%)
|
-103.79M
est: -80.93M (-28.3%)
|
-5.06M
est: -83.62M (+94.0%)
|
-17.88M
est: -91.54M (+80.5%)
|
-102.76M
-104.11M – -101.41M
-12.3% YoY
|
-116.70M
-120.16M – -113.41M
-13.6% YoY
|
-132.16M
-132.17M – -132.16M
-13.3% YoY
|
-156.15M
-160.77M – -151.75M
-18.1% YoY
|
-175.23M
-180.42M – -170.29M
-12.2% YoY
|
| EBIT |
-170.48M
est: -156.64M (-8.8%)
|
-193.55M
est: -175.99M (-10.0%)
|
-176.17M
est: -173.16M (-1.7%)
|
-203.28M
est: -110.49M (-84.0%)
|
-225.38M
est: -233.51M (+3.5%)
|
-218.27M
est: -225.29M (+3.1%)
|
-179.55M
est: -216.17M (+16.9%)
|
-106.69M
est: -82.43M (-29.4%)
|
-7.55M
est: -85.17M (+91.1%)
|
-20.20M
est: -93.24M (+78.3%)
|
-104.67M
-106.04M – -103.30M
-12.3% YoY
|
-118.86M
-122.38M – -115.51M
-13.6% YoY
|
-134.61M
-134.62M – -134.61M
-13.3% YoY
|
-159.04M
-163.75M – -154.56M
-18.1% YoY
|
-178.48M
-183.76M – -173.45M
-12.2% YoY
|
| Net Income |
-173.14M
est: -158.74M (-9.1%)
|
-197.48M
est: -178.74M (-10.5%)
|
-178.84M
est: -168.99M (-5.8%)
|
-204.75M
est: -365.27M (+43.9%)
|
-227.28M
est: -232.41M (+2.2%)
|
-220.68M
est: -228.29M (+3.3%)
|
-182.02M
est: -136.60M (-33.2%)
|
-110.56M
est: -52.03M (-112.5%)
|
-13.58M
est: -21.50M (+36.8%)
|
-20.20M
est: -15.02M (-34.5%)
|
-4.75M
-7.41M – -2.78M
+68.4% YoY
|
12.51M
12.05M – 12.98M
+363.5% YoY
|
29.20M
28.11M – 30.30M
+133.3% YoY
|
43.34M
41.76M – 45.01M
+48.4% YoY
|
55.01M
53.00M – 57.13M
+26.9% YoY
|
| SGA |
69.03M
est: 1.23M (+5,510.4%)
|
82.16M
est: 34.02M (+141.5%)
|
93.87M
est: 85.65M (+9.6%)
|
127.66M
est: 160.54M (-20.5%)
|
106.08M
est: 99.09M (+7.1%)
|
127.33M
est: 103.88M (+22.6%)
|
144.75M
est: 118.65M (+22.0%)
|
119.82M
est: 139.85M (-14.3%)
|
100.48M
est: 144.49M (-30.5%)
|
103.67M
est: 158.18M (-34.5%)
|
177.58M
175.25M – 179.91M
+12.3% YoY
|
201.66M
195.98M – 207.63M
+13.6% YoY
|
228.38M
228.37M – 228.39M
+13.3% YoY
|
269.83M
262.22M – 277.82M
+18.1% YoY
|
302.80M
294.27M – 311.77M
+12.2% YoY
|
| EPS |
-4.57
est: -4.51 (-1.2%)
|
-3.65
est: -3.34 (-9.4%)
|
-2.44
est: -2.28 (-7.2%)
|
-2.50
est: -2.40 (-4.3%)
|
-2.50
est: -2.47 (-1.4%)
|
-2.24
est: -2.28 (+1.9%)
|
-1.67
est: -1.85 (+9.6%)
|
-0.80
est: -0.31 (-156.6%)
|
-0.09
est: -0.13 (+30.9%)
|
-0.12
est: -0.09 (-33.3%)
|
-0.03
-0.04 – -0.02
+63.0% YoY
|
0.08
0.07 – 0.08
+325.0% YoY
|
0.18
0.17 – 0.18
+133.3% YoY
|
0.26
0.25 – 0.27
+48.6% YoY
|
0.33
0.32 – 0.34
+26.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-20.37M
OE per share TTM
-0.13
Owner's Yield
-11.24%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
22.4%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
68
Total invested
21.38M
Insider transactions (90d)
8
Beneficial owners (>5%)
35
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Board of Directors of MetLife, Inc., as an entity | 172.03M | 15.50% | — | 4.92M | — | 4.92M | IC | Jersey Channel Islands | 2020-02-13 | ↗ |
| 2 | STATE STREET CORPORATION | 12.92M | 12.65% | — | — | — | 12.92M | HC | BOSTON, MASSACHUSETTS | 2022-04-11 | ↗ |
| 3 | David Kroin | 12.23M | 9.99% | — | 12.23M | — | — | HC, IN | Delaware | 2022-08-19 | ↗ |
| 4 | Deep Track Biotechnology Master Fund, Ltd. | 12.23M | 9.99% | — | 12.23M | — | — | CO | Delaware | 2022-08-19 | ↗ |
| 5 | Deep Track Capital, LP | 12.23M | 9.99% | — | 12.23M | — | — | IA, OO | Delaware | 2022-08-19 | ↗ |
| 6 | David Rosen | 11.75M | 9.90% | — | — | — | 11.75M | IN | — | 2023-02-06 | ↗ |
| 7 | Rubric Capital Management LP | 11.75M | 9.90% | — | — | — | 11.75M | IA, PN | — | 2023-02-06 | ↗ |
| 8 | SSGA FUNDS MANAGEMENT, INC. | 11.04M | 10.81% | — | — | — | 11.04M | IA | BOSTON, MASSACHUSETTS | 2022-04-11 | ↗ |
| 9 | The Vanguard Group - 23-1945930 | 9.61M | 9.43% | — | 177.4K | 9.35M | 257.0K | IA | Pennsylvania For | 2022-02-10 | ↗ |
| 10 | Adage Capital Management, L.P. | 8.85M | 5.84% | — | 8.85M | — | — | IA, PN | Delaware | 2024-11-12 | ↗ |
| 11 | Phillip Gross | 8.85M | 5.84% | — | 8.85M | — | — | HC, IN | Delaware | 2024-11-12 | ↗ |
| 12 | Robert Atchinson | 8.85M | 5.84% | — | 8.85M | — | — | HC, IN | Delaware | 2024-11-12 | ↗ |
| 13 | (1) BlackRock, Inc. | 8.53M | 5.60% | — | — | 8.53M | — | HC | Delaware | 2024-10-24 | ↗ |
| 14 | UBS O’Connor LLC | 8.28M | 8.12% | 8.28M | — | 8.28M | — | IA, OO | Delaware | 2022-02-14 | ↗ |
| 15 | Baker Bros. Advisors LP | 8.13M | 8.00% | 8.13M | — | 8.13M | — | IA, PN | — | 2022-02-14 | ↗ |
| 16 | Baker Bros. Advisors (GP) LLC | 8.06M | 8.70% | 8.06M | — | 8.06M | — | OO | Delaware | 2021-02-16 | ↗ |
| 17 | Felix J. Baker | 8.06M | 8.70% | 8.06M | — | 8.06M | — | HC, IN | United States | 2021-02-16 | ↗ |
| 18 | Julian C. Baker | 8.06M | 8.70% | 8.06M | — | 8.06M | — | HC, IN | United States | 2021-02-16 | ↗ |
| 19 | ArrowMark Colorado Holdings, LLC | 6.41M | 6.28% | 6.41M | — | 6.41M | — | IA | Delaware, United States | 2022-02-14 | ↗ |
| 20 | Dr. Jeffrey R. Jay, M.D. | 6.36M | 5.35% | — | 6.36M | — | — | HC, IN | Delaware | 2023-04-13 | ↗ |
| 21 | Great Point Partners, LLC | 6.36M | 5.35% | — | 6.36M | — | — | IA, OO | Delaware | 2023-04-13 | ↗ |
| 22 | Mr. Ortav Yehudai | 6.36M | 5.35% | — | 6.36M | — | — | HC, IN | Delaware | 2023-04-13 | ↗ |
| 23 | JPMORGAN CHASE & CO.13-2624428 | 6.25M | 6.10% | 5.60M | — | 6.25M | 27.00 | HC | Delaware | 2022-01-24 | ↗ |
| 24 | Wellington Management Company LLP | 5.97M | 6.57% | — | 5.81M | — | — | IA | Massachusetts | 2021-02-04 | ↗ |
| 25 | Adam Morgan | 4.50M | 3.80% | — | — | — | 4.50M | IN | — | 2023-02-06 | ↗ |
| 26 | Balaji Venkataraman | 4.50M | 3.80% | — | — | — | 4.50M | IN | — | 2023-02-06 | ↗ |
| 27 | Velan Capital Holdings LLC | 4.50M | 3.80% | — | — | — | 4.50M | OO | — | 2023-02-06 | ↗ |
| 28 | Velan Capital Investment Management LP | 4.50M | 3.80% | — | — | — | 4.50M | PN | — | 2023-02-06 | ↗ |
| 29 | Velan Capital Management LLC | 4.50M | 3.80% | — | — | — | 4.50M | OO | — | 2023-02-06 | ↗ |
| 30 | Velan Capital Master Fund LP | 4.50M | 3.80% | — | — | — | 4.50M | PN | — | 2023-02-06 | ↗ |
| 31 | Wellington Group Holdings LLP | 1.64M | 1.61% | — | 1.53M | — | — | HC | Delaware | 2022-02-04 | ↗ |
| 32 | Wellington Investment Advisors Holdings LLP | 1.64M | 1.61% | — | 1.53M | — | — | HC | Delaware | 2022-02-04 | ↗ |
| 33 | Wellington Management Group LLP | 1.64M | 1.61% | — | 1.53M | — | — | HC | Massachusetts | 2022-02-04 | ↗ |
| 34 | EIN #00-0000000 | — | 0.00% | — | — | — | — | IA, HC | Jersey Channel Islands | 2021-02-11 | ↗ |
| 35 | Pershing Square Capital Management, L.P. | — | 0.00% | 4.00 | 4.00 | 4.00 | 4.00 | IA | Delaware | 2022-02-03 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
68
-106 vs prev Q
New positions
17
Closed positions
120
Increased
33
Reduced
10
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | RUBRIC CAPITAL MANAGEMENT LP | 30.05M +946.1K (+3.3%) | 39.06M +2.4M (+6.5%) | 17.64% -1.256 pp | 0.47% +0.053 pp | USD1.78 -27.0% | 14 qtrs — |
| 2 | CLEARLINE CAPITAL LP | 12.24M +2.5M (+26.0%) | 15.91M +3.7M (+30.0%) | 7.18% +0.876 pp | 0.78% +0.223 pp | USD1.29 +0.8% | 13 qtrs — |
| 3 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 11.19M +946.1K (+9.2%) | 14.54M +1.6M (+12.7%) | 6.57% -0.082 pp | 0.02% +0.002 pp | USD2.16 -39.8% | 11 qtrs — |
| 4 | BLACKROCK, INC. | 10.22M +230.8K (+2.3%) | 13.28M +699.5K (+5.6%) | 6.00% -0.486 pp | 0.00% +0.000 pp | USD1.98 -34.3% | 6 qtrs — |
| 5 | VANGUARD GROUP INC | 9.82M +1.4M (+16.1%) | 12.77M +2.1M (+19.8%) | 5.76% +0.272 pp | 0.00% +0.000 pp | USD15.92 -91.8% | 47 qtrs — |
| 6 | VELAN CAPITAL INVESTMENT MANAGEMENT LP | 8.75M +— (+0.0%) | 11.38M +350.1K (+3.2%) | 5.14% -0.545 pp | 6.60% -3.758 pp | USD1.61 -19.3% | 13 qtrs — |
| 7 | MILLENNIUM MANAGEMENT LLC | 7.17M +6.9M (+2,785.2%) | 9.32M +9.0M (+2,876.8%) | 4.21% +4.048 pp | 0.00% +0.004 pp | USD1.33 -2.3% | 37 qtrs — |
| 8 | PALISADE CAPITAL MANAGEMENT, LP | 6.33M -1.0M (-13.7%) | 8.22M -1.0M (-10.9%) | 3.71% -1.044 pp | 0.24% -0.007 pp | USD6.22 -79.1% | 29 qtrs — |
| 9 | TANG CAPITAL MANAGEMENT LLC | 6.25M +2.8M (+81.2%) | 8.13M +3.8M (+86.9%) | 3.67% +1.429 pp | 0.40% +0.234 pp | USD2.05 -36.6% | 19 qtrs — |
| 10 | TEJARA CAPITAL LTD | 5.13M +541.7K (+11.8%) | 6.67M +887.8K (+15.4%) | 3.01% +0.032 pp | 1.57% -1.447 pp | USD1.69 -23.1% | 13 qtrs — |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 4.08M +438.2K (+12.0%) | 5.31M +715.4K (+15.6%) | 2.40% +0.031 pp | 0.00% +0.000 pp | USD9.27 -86.0% | 48 qtrs — |
| 12 | STATE STREET CORP | 3.78M +126.5K (+3.5%) | 4.91M +310.6K (+6.8%) | 2.22% -0.153 pp | 0.00% +0.000 pp | USD5.53 -76.5% | 48 qtrs — |
| 13 | JW ASSET MANAGEMENT, LLC | 3.67M +378.4K (+11.5%) | 4.77M +623.7K (+15.0%) | 2.16% +0.017 pp | 1.55% -0.438 pp | USD1.21 +7.4% | 11 qtrs — |
| 14 | CONGRESS PARK CAPITAL LLC | 3.07M +177.3K (+6.1%) | 3.99M +346.1K (+9.5%) | 1.80% -0.076 pp | 1.19% +0.059 pp | USD1.99 -34.7% | 33 qtrs — |
| 15 | D. E. SHAW & CO., INC. | 3.00M -83.9K (-2.7%) | 3.91M +14.5K (+0.4%) | 1.76% -0.241 pp | 0.00% 0.000 pp | USD3.33 -61.0% | 45 qtrs — |
| 16 | COLONY GROUP, LLC | 148.5K +129.9K (+697.6%) | 3.57M +3.5M (+15,122.9%) | 0.09% +0.075 pp | 0.00% +0.004 pp | USD1.29 +0.8% | 2 qtrs — |
| 17 | NEW YORK STATE COMMON RETIREMENT FUND | 2.58M +— (+0.0%) | 3.35M +103.1K (+3.2%) | 1.51% -0.160 pp | 0.00% +0.000 pp | USD5.87 -77.9% | 43 qtrs — |
| 18 | CITADEL ADVISORS LLC | 2.10M -613.4K (-22.6%) | 2.72M -689.1K (-20.2%) | 1.23% -0.529 pp | 0.00% 0.000 pp | USD1.95 -33.3% | 45 qtrs — |
| 19 | UBS GROUP AG | 2.09M -842.4K (-28.7%) | 2.72M -977.8K (-26.4%) | 1.23% -0.677 pp | 0.00% 0.000 pp | USD2.08 -37.5% | 45 qtrs — |
| 20 | RENAISSANCE TECHNOLOGIES LLC | 1.92M -939.1K (-32.9%) | 2.49M -1.1M (-30.8%) | 1.12% -0.729 pp | 0.00% -0.001 pp | USD2.01 -35.3% | 13 qtrs — |
| 21 | PALE FIRE CAPITAL SE | 1.47M +998.5K (+211.9%) | 1.91M +1.3M (+221.8%) | 0.86% +0.557 pp | 0.13% +0.063 pp | USD1.29 +0.8% | 2 qtrs — |
| 22 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.42M +138.3K (+10.8%) | 1.84M +230.9K (+14.3%) | 0.83% +0.002 pp | 0.00% +0.000 pp | USD9.88 -86.8% | 47 qtrs — |
| 23 | JANE STREET GROUP, LLC | 1.37M +1.1M (+520.9%) | 1.78M +1.5M (+540.6%) | 0.80% +0.660 pp | 0.00% +0.000 pp | USD1.43 -9.1% | 26 qtrs — |
| 24 | STONEPINE CAPITAL MANAGEMENT, LLC | 1.24M +387.7K (+45.6%) | 1.61M +538.0K (+50.2%) | 0.73% +0.175 pp | 1.17% +0.304 pp | USD1.46 -11.0% | 5 qtrs — |
| 25 | MONACO ASSET MANAGEMENT SAM | 1.23M +230.5K (+23.0%) | 1.60M +339.8K (+26.9%) | 0.72% +0.073 pp | 0.28% +0.201 pp | USD1.56 -16.7% | 11 qtrs — |
| 26 | NORTHERN TRUST CORP | 1.09M -66.2K (-5.7%) | 1.42M -39.7K (-2.7%) | 0.64% -0.111 pp | 0.00% +0.000 pp | USD13.80 -90.6% | 48 qtrs — |
| 27 | TWO SIGMA INVESTMENTS, LP | 999.5K +307.2K (+44.4%) | 1.30M +427.1K (+49.0%) | 0.59% +0.137 pp | 0.00% +0.001 pp | USD2.52 -48.4% | 8 qtrs — |
| 28 | GOLDMAN SACHS GROUP INC | 989.8K -335.0K (-25.3%) | 1.29M -382.5K (-22.9%) | 0.58% -0.279 pp | 0.00% +0.000 pp | USD2.79 -53.4% | 43 qtrs — |
| 29 | MORGAN STANLEY | 963.9K -1.5M (-60.9%) | 1.25M -1.9M (-59.7%) | 0.57% -1.037 pp | 0.00% 0.000 pp | USD2.29 -43.2% | 48 qtrs — |
| 30 | CM MANAGEMENT, LLC | 750.0K +— (+0.0%) | 975.0K +30.0K (+3.2%) | 0.44% -0.047 pp | 0.82% +0.034 pp | USD2.53 -48.6% | 21 qtrs — |
| 31 | ORCHARD CAPITAL MANAGEMENT, LLC | 680.4K +3.1K (+0.5%) | 884.6K +31.2K (+3.7%) | 0.40% -0.040 pp | 0.77% +0.030 pp | USD5.08 -74.4% | 19 qtrs — |
| 32 | SQUAREPOINT OPS LLC | 677.9K +462.8K (+215.2%) | 881.3K +610.3K (+225.2%) | 0.40% +0.258 pp | 0.00% +0.001 pp | USD1.36 -4.4% | 3 qtrs — |
| 33 | RICHMOND BROTHERS, INC. | 572.1K +— (+0.0%) | 743.8K +22.9K (+3.2%) | 0.34% -0.036 pp | 0.47% +0.018 pp | USD1.79 -27.4% | 11 qtrs — |
| 34 | TWO SIGMA ADVISERS, LP | 519.6K +337.5K (+185.4%) | 675.4K +446.0K (+194.4%) | 0.31% +0.187 pp | 0.00% +0.001 pp | USD1.60 -18.8% | 14 qtrs — |
| 35 | NEXPOINT ASSET MANAGEMENT, L.P. | 475.8K +— (+0.0%) | 618.5K +19.0K (+3.2%) | 0.28% -0.030 pp | 0.04% -0.009 pp | USD18.50 -93.0% | 26 qtrs — |
| 36 | PANAGORA ASSET MANAGEMENT INC | 440.3K +440.3K (+100.0%) | 572.3K +572.3K (+100.0%) | 0.26% +0.258 pp | 0.00% +0.002 pp | USD1.30 +0.0% | 1 qtrs NEW |
| 37 | BANK OF NEW YORK MELLON CORP | 418.5K +6.0K (+1.5%) | 544.0K +24.3K (+4.7%) | 0.25% -0.022 pp | 0.00% +0.000 pp | USD9.62 -86.5% | 47 qtrs — |
| 38 | AQR CAPITAL MANAGEMENT LLC | 376.3K -1.6M (-80.6%) | 489.2K -2.0M (-80.0%) | 0.22% -1.037 pp | 0.00% -0.001 pp | USD1.30 +0.0% | 14 qtrs — |
| 39 | NUVEEN, LLC | 347.1K +— (+0.0%) | 451.2K +13.9K (+3.2%) | 0.20% -0.022 pp | 0.00% +0.000 pp | USD2.19 -40.6% | 4 qtrs — |
| 40 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 340.2K +11.3K (+3.4%) | 442.3K +27.8K (+6.7%) | 0.20% -0.014 pp | 0.00% +0.000 pp | USD2.38 -45.4% | 47 qtrs — |
| 41 | CAPTION MANAGEMENT, LLC | 339.1K +339.1K (+100.0%) | 440.8K +440.8K (+100.0%) | 0.20% +0.199 pp | 0.00% +0.003 pp | USD1.30 +0.0% | 3 qtrs — |
| 42 | INVESCO LTD. | 307.9K +76.5K (+33.0%) | 400.2K +108.7K (+37.3%) | 0.18% +0.031 pp | 0.00% +0.000 pp | USD2.74 -52.6% | 43 qtrs — |
| 43 | BARCLAYS PLC | 303.2K +84.8K (+38.8%) | 394.2K -40.6K (-9.3%) | 0.18% +0.036 pp | 0.00% +0.000 pp | USD2.09 -37.8% | 47 qtrs — |
| 44 | APEIRON RIA LLC | 260.0K +37.1K (+16.6%) | 358.8K +69.0K (+23.8%) | 0.15% +0.008 pp | 0.07% +0.008 pp | USD2.07 -37.2% | 12 qtrs — |
| 45 | PALUMBO WEALTH MANAGEMENT LLC | 259.4K +42.9K (+19.8%) | 337.2K +64.4K (+23.6%) | 0.15% +0.012 pp | 0.08% -0.004 pp | USD1.74 -25.3% | 4 qtrs — |
| 46 | CYNDEO WEALTH PARTNERS, LLC | 248.1K +— (+0.0%) | 322.5K +9.9K (+3.2%) | 0.15% -0.015 pp | 0.02% +0.000 pp | USD2.07 -37.2% | 3 qtrs — |
| 47 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 242.0K -458.0K (-65.4%) | 314.6K -567.4K (-64.3%) | 0.14% -0.312 pp | 0.01% -0.012 pp | USD1.91 -31.9% | 5 qtrs — |
| 48 | XTX TOPCO LTD | 240.2K +209.7K (+687.6%) | 312.3K +273.8K (+712.6%) | 0.14% +0.121 pp | 0.01% +0.006 pp | USD1.29 +0.8% | 20 qtrs — |
| 49 | QUADRATURE CAPITAL LTD | 227.8K +227.8K (+100.0%) | 296.1K +296.1K (+100.0%) | 0.13% +0.134 pp | 0.00% +0.003 pp | USD1.30 +0.0% | 1 qtrs NEW |
| 50 | LOS ANGELES CAPITAL MANAGEMENT LLC | 248.6K +2.2K (+0.9%) | 283.4K -27.1K (-8.7%) | 0.15% -0.014 pp | 0.00% 0.000 pp | USD2.04 -36.3% | 14 qtrs — |
| 51 | RHUMBLINE ADVISERS | 203.3K -21.3K (-9.5%) | 264.3K -18.7K (-6.6%) | 0.12% -0.027 pp | 0.00% +0.000 pp | USD10.04 -87.1% | 47 qtrs — |
| 52 | ALLIANCEBERNSTEIN L.P. | 198.6K +— (+0.0%) | 258.1K +7.9K (+3.2%) | 0.12% -0.012 pp | 0.00% +0.000 pp | USD7.91 -83.6% | 47 qtrs — |
| 53 | WELLS FARGO & COMPANY/MN | 179.6K +56.5K (+45.9%) | 233.5K +78.4K (+50.5%) | 0.11% +0.026 pp | 0.00% +0.000 pp | USD2.07 -37.2% | 48 qtrs — |
| 54 | QUINN OPPORTUNITY PARTNERS LLC | 175.3K +— (+0.0%) | 227.9K +7.0K (+3.2%) | 0.10% -0.011 pp | 0.01% -0.006 pp | USD1.53 -15.0% | 5 qtrs — |
| 55 | GROUP ONE TRADING, L.P. | 145.2K +145.2K (+100.0%) | 188.7K +188.7K (+100.0%) | 0.09% +0.085 pp | 0.00% +0.000 pp | USD1.30 +0.0% | 1 qtrs NEW |
| 56 | CAPITAL PLANNING ADVISORS, LLC | 144.1K +— (+0.0%) | 187.3K +5.8K (+3.2%) | 0.08% -0.009 pp | 0.03% +0.000 pp | USD2.03 -36.0% | 10 qtrs — |
| 57 | GSA CAPITAL PARTNERS LLP | 135.1K +34.9K (+34.8%) | 176.0K +50.0K (+39.7%) | 0.08% +0.014 pp | 0.02% +0.005 pp | USD1.87 -30.5% | 3 qtrs — |
| 58 | BANK OF AMERICA CORP /DE/ | 134.4K -597.6K (-81.6%) | 174.8K -747.6K (-81.1%) | 0.08% -0.396 pp | 0.00% +0.000 pp | USD2.47 -47.4% | 47 qtrs — |
| 59 | RAYMOND JAMES FINANCIAL INC | 120.2K +8.5K (+7.6%) | 156.3K +15.6K (+11.1%) | 0.07% -0.002 pp | 0.00% +0.000 pp | USD1.51 -13.9% | 5 qtrs — |
| 60 | SIMPLEX TRADING, LLC | 114.6K +87.7K (+326.5%) | 149.0K +116.0K (+351.5%) | 0.07% +0.050 pp | 0.00% +0.000 pp | USD1.48 -12.2% | 32 qtrs — |
| 61 | BILTMORE FAMILY OFFICE, LLC | 100.0K +— (+0.0%) | 130.0K +4.0K (+3.2%) | 0.06% -0.006 pp | 0.02% +0.000 pp | USD1.53 -15.0% | 5 qtrs — |
| 62 | INTEGRATED WEALTH CONCEPTS LLC | 95.2K -2.4K (-2.5%) | 123.7K +756.0 (+0.6%) | 0.06% -0.008 pp | 0.00% +0.000 pp | USD1.77 -26.6% | 9 qtrs — |
| 63 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 94.0K +10.3K (+12.3%) | 122.2K +16.8K (+15.9%) | 0.06% +0.001 pp | 0.00% +0.000 pp | USD1.26 +3.2% | 2 qtrs — |
| 64 | DEUTSCHE BANK AG\ | 93.1K +7.9K (+9.3%) | 121.0K +13.7K (+12.8%) | 0.05% -0.001 pp | 0.00% +0.000 pp | USD5.24 -75.2% | 48 qtrs — |
| 65 | METLIFE INVESTMENT MANAGEMENT, LLC | 87.8K -4.7K (-5.1%) | 114.1K -2.4K (-2.0%) | 0.05% -0.009 pp | 0.00% +0.000 pp | USD6.75 -80.7% | 33 qtrs — |
| 66 | SEARLE & CO. | 86.3K +— (+0.0%) | 112.1K +3.5K (+3.2%) | 0.05% -0.005 pp | 0.03% +0.000 pp | USD2.58 -49.6% | 27 qtrs — |
| 67 | FMR LLC | 84.2K +36.8K (+77.7%) | 109.5K +49.7K (+83.3%) | 0.05% +0.019 pp | 0.00% +0.000 pp | USD4.94 -73.7% | 43 qtrs — |
| 68 | GLENMEDE TRUST CO NA | 82.2K +82.2K (+100.0%) | 106.8K +106.8K (+100.0%) | 0.05% +0.048 pp | 0.00% +0.001 pp | USD1.30 +0.0% | 1 qtrs NEW |
| 69 | PRICE T ROWE ASSOCIATES INC /MD/ | 76.6K +— (+0.0%) | 100.0K +3.0K (+3.1%) | 0.05% -0.005 pp | 0.00% +0.000 pp | USD2.27 -42.7% | 31 qtrs — |
| 70 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 71.4K -491.0 (-0.7%) | 92.8K +2.2K (+2.5%) | 0.04% -0.005 pp | 0.00% +0.000 pp | USD3.09 -57.9% | 7 qtrs — |
| 71 | JPMORGAN CHASE & CO | 62.4K -1.2M (-95.2%) | 81.1K -1.5M (-95.0%) | 0.04% -0.803 pp | 0.00% 0.000 pp | USD2.10 -38.1% | 42 qtrs — |
| 72 | COMMONWEALTH EQUITY SERVICES, LLC | 59.4K -620.0 (-1.0%) | 77.3K +1.3K (+1.6%) | 0.03% -0.004 pp | 0.00% +0.000 pp | USD2.53 -48.6% | 8 qtrs — |
| 73 | INTECH INVESTMENT MANAGEMENT LLC | 59.4K -14.0K (-19.1%) | 77.2K -15.3K (-16.5%) | 0.03% -0.013 pp | 0.00% 0.000 pp | USD1.94 -33.0% | 6 qtrs — |
| 74 | STATE OF WYOMING | 58.6K +58.6K (+100.0%) | 76.2K +76.2K (+100.0%) | 0.03% +0.034 pp | 0.01% +0.008 pp | USD1.30 +0.0% | 1 qtrs NEW |
| 75 | CORNERSTONE SELECT ADVISORS, LLC | 58.1K -1.0K (-1.7%) | 75.5K +1.1K (+1.4%) | 0.03% -0.004 pp | 0.05% -0.002 pp | USD1.49 -12.8% | 5 qtrs — |
| 76 | LPL FINANCIAL LLC | 55.9K +5.3K (+10.4%) | 72.7K +8.9K (+13.9%) | 0.03% 0.000 pp | 0.00% +0.000 pp | USD3.72 -65.1% | 23 qtrs — |
| 77 | HEADLANDS TECHNOLOGIES LLC | 51.3K +31.4K (+158.3%) | 66.7K +41.7K (+166.5%) | 0.03% +0.017 pp | 0.01% +0.004 pp | USD1.77 -26.6% | 8 qtrs — |
| 78 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 48.7K -3.3K (-6.4%) | 63.3K -2.2K (-3.4%) | 0.03% -0.005 pp | 0.00% +0.000 pp | USD2.10 -38.1% | 47 qtrs — |
| 79 | ATOM INVESTORS LP | 48.2K +48.2K (+100.0%) | 62.6K +62.6K (+100.0%) | 0.03% +0.028 pp | 0.01% +0.005 pp | USD1.30 +0.0% | 1 qtrs NEW |
| 80 | ABEL HALL, LLC | 46.2K +46.2K (+100.0%) | 60.0K +60.0K (+100.0%) | 0.03% +0.027 pp | 0.01% +0.014 pp | USD1.30 +0.0% | 1 qtrs NEW |
| 81 | CAPTRUST FINANCIAL ADVISORS | 41.6K -7.4K (-15.0%) | 54.1K -7.6K (-12.3%) | 0.02% -0.007 pp | 0.00% +0.000 pp | USD2.05 -36.6% | 3 qtrs — |
| 82 | PROSPERA FINANCIAL SERVICES INC | 40.6K -11.1K (-21.5%) | 52.7K -12.4K (-19.0%) | 0.02% -0.010 pp | 0.00% 0.000 pp | USD2.04 -36.3% | 3 qtrs — |
| 83 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 38.4K +— (+0.0%) | 49.9K +1.5K (+3.2%) | 0.02% -0.002 pp | 0.00% +0.000 pp | USD1.72 -24.4% | 5 qtrs — |
| 84 | CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD | 35.1K +27.0K (+335.2%) | 45.6K +35.5K (+349.1%) | 0.02% +0.015 pp | 0.01% +0.004 pp | USD1.34 -3.0% | 5 qtrs — |
| 85 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 35.0K +35.0K (+100.0%) | 45.5K +45.5K (+100.0%) | 0.02% +0.021 pp | 0.00% +0.001 pp | USD1.30 +0.0% | 4 qtrs — |
| 86 | HSBC HOLDINGS PLC | 33.4K -53.0 (-0.2%) | 43.9K +1.9K (+4.6%) | 0.02% -0.002 pp | 0.00% +0.000 pp | USD2.44 -46.7% | 8 qtrs — |
| 87 | BNP PARIBAS ARBITRAGE, SNC | 32.9K -345.7K (-91.3%) | 42.7K -434.3K (-91.0%) | 0.02% -0.227 pp | 0.00% 0.000 pp | USD2.41 -46.1% | 46 qtrs — |
| 88 | CONCURRENT INVESTMENT ADVISORS, LLC | 31.9K +31.9K (+100.0%) | 41.5K +41.5K (+100.0%) | 0.02% +0.019 pp | 0.00% +0.001 pp | USD1.30 +0.0% | 1 qtrs NEW |
| 89 | KING WEALTH | 30.8K +1.0K (+3.4%) | 40.0K +2.0K (+5.3%) | 0.02% -0.001 pp | 0.00% +0.000 pp | USD2.38 -45.4% | 8 qtrs — |
| 90 | ANFIELD CAPITAL MANAGEMENT, LLC | 30.0K +— (+0.0%) | 39.0K +1.2K (+3.2%) | 0.02% -0.002 pp | 0.01% +0.001 pp | USD2.00 -35.0% | 6 qtrs — |
| 91 | CORECAP ADVISORS, LLC | 28.4K +— (+0.0%) | 36.9K +1.1K (+3.2%) | 0.02% -0.002 pp | 0.00% +0.000 pp | USD2.20 -40.9% | 5 qtrs — |
| 92 | PROSHARE ADVISORS LLC | 28.1K +1.9K (+7.3%) | 36.5K +3.5K (+10.7%) | 0.02% -0.001 pp | 0.00% +0.000 pp | USD3.95 -67.1% | 25 qtrs — |
| 93 | JONES FINANCIAL COMPANIES LLLP | 28.0K +3.9K (+16.1%) | 36.3K +7.2K (+24.7%) | 0.02% +0.001 pp | 0.00% +0.000 pp | USD1.28 +1.6% | 5 qtrs — |
| 94 | VOYA INVESTMENT MANAGEMENT LLC | 27.7K +— (+0.0%) | 35.9K +1.1K (+3.2%) | 0.02% -0.002 pp | 0.00% +0.000 pp | USD12.07 -89.2% | 47 qtrs — |
| 95 | VALEO FINANCIAL ADVISORS, LLC | 26.7K +— (+0.0%) | 34.7K +1.1K (+3.2%) | 0.02% -0.002 pp | 0.00% +0.000 pp | USD2.49 -47.8% | 7 qtrs — |
| 96 | CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. | 26.4K -200.0 (-0.8%) | 34.0K +— (+0.0%) | 0.02% -0.002 pp | 0.00% +0.000 pp | USD5.40 -75.9% | 19 qtrs — |
| 97 | ACT ADVISORS, LLC. | 25.8K +227.0 (+0.9%) | 33.6K +1.3K (+4.1%) | 0.02% -0.002 pp | 0.01% +0.000 pp | USD1.74 -25.3% | 9 qtrs — |
| 98 | — | 25.0K +25.0K (+100.0%) | 32.5K +32.5K (+100.0%) | 0.01% +0.015 pp | 0.00% +0.004 pp | USD1.30 +0.0% | 1 qtrs NEW |
| 99 | SG AMERICAS SECURITIES, LLC | 24.4K +6.9K (+39.1%) | 32.0K +10.0K (+45.5%) | 0.01% +0.003 pp | 0.00% +0.000 pp | USD2.85 -54.4% | 15 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 54 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco NASDAQ Future Gen 200 ETF QQQS | 0.24% | 52.2K | 0.20% |
| 2 | iShares Micro-Cap ETF IWC | 0.01% | 222.7K | 0.60% |
| 3 | Vanguard Russell 2000 Value ETF VTWV | 0.01% | 91.0K | 0.06% |
| 4 | Vanguard Russell 2000 ETF VTWO | 0.00% | 665.9K | 0.06% |
| 5 | iShares Russell 2000 Growth ETF IWO | 0.00% | 565.6K | 0.24% |
| 6 | Invesco RAFI US 1500 Small-Mid ETF PRFZ | 0.00% | 82.3K | 0.34% |
| 7 | Vanguard Health Care ETF VHT | 0.00% | 409.6K | 0.09% |
| 8 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.00% | 6.8K | 0.25% |
| 9 | Global X - Russell 2000 ETF RSSL | 0.00% | 31.0K | 0.08% |
| 10 | iShares Russell 2000 BuyWrite ETF IWMW | 0.00% | 1.1K | 0.39% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.00
Neutral
Ratio by volume
1.00
Neutral
Buys
12
Sells
12
Shares acquired
354.3K
Shares disposed
354.3K
Cash buys
—
Cash sales
—
Net activity
+0
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | Hensley Mark Earl | Officer | M-Exempt | D | Restricted Stock Units | 125,000 | 0.00 | — | 375,000 | D | ↗ |
| 2026-04-30 | Hensley Mark Earl | Officer | M-Exempt | A | Common Stock | 11,770 | 0.00 | — | 11,770 | D | ↗ |
| 2026-04-30 | Forbes William P | Officer | M-Exempt | D | Restricted Stock Units | 11,694 | 0.00 | — | 128,638 | D | ↗ |
| 2026-04-30 | Duarte Ira | Officer | M-Exempt | A | Common Stock | 11,694 | 0.00 | — | 227,570 | D | ↗ |
| 2026-04-30 | Collard Craig A | Director / Officer | M-Exempt | D | Restricted Stock Units | 34,789 | 0.00 | — | 382,675 | D | ↗ |
| 2026-04-19 | Forbes William P | Officer | M-Exempt | A | Common Stock | 3,874 | 0.00 | — | 185,647 | D | ↗ |
| 2026-04-19 | Duarte Ira | Officer | M-Exempt | D | Restricted Stock Units | 3,874 | 0.00 | — | 27,120 | D | ↗ |
| 2026-04-19 | Collard Craig A | Director / Officer | M-Exempt | D | Restricted Stock Units | 13,797 | 0.00 | — | 96,758 | D | ↗ |
| 2026-04-03 | Collard Craig A | Director / Officer | M-Exempt | A | Common Stock | 62,500 | 0.00 | — | 648,255 | D | ↗ |
| 2026-01-31 | Forbes William P | Officer | M-Exempt | D | Restricted Stock Units | 11,695 | 0.00 | — | 140,332 | D | ↗ |
| 2026-01-31 | Duarte Ira | Officer | M-Exempt | D | Restricted Stock Units | 11,695 | 0.00 | — | 140,332 | D | ↗ |
| 2026-01-31 | Collard Craig A | Director / Officer | M-Exempt | D | Restricted Stock Units | 34,789 | 0.00 | — | 417,464 | D | ↗ |
| 2026-01-30 | Morgan Adam | Director | A-Award | A | Common Stock | 53,960 | 0.00 | — | 123,737 | D | ↗ |
| 2026-01-30 | Kaseta Michael | Director | A-Award | A | Common Stock | 53,960 | 0.00 | — | 53,960 | D | ↗ |
| 2026-01-30 | Johnson Craig A | Director | A-Award | A | Common Stock | 53,960 | 0.00 | — | 53,960 | D | ↗ |
| 2026-01-30 | Hensley Mark Earl | Officer | A-Award | A | Performance Stock Units | 188,314 | 0.00 | — | 188,314 | D | ↗ |
| 2026-01-30 | Forbes William P | Officer | A-Award | A | Performance Stock Units | 188,314 | 0.00 | — | 188,314 | D | ↗ |
| 2026-01-30 | Duarte Ira | Officer | A-Award | A | Performance Stock Units | 216,561 | 0.00 | — | 216,561 | D | ↗ |
| 2026-01-30 | Dissanaike Sharmila | Director | A-Award | A | Common Stock | 53,960 | 0.00 | — | 53,960 | D | ↗ |
| 2026-01-30 | Cusack Thomas | Director | A-Award | A | Common Stock | 53,960 | 0.00 | — | 53,960 | D | ↗ |
| 2026-01-30 | Collard Craig A | Director / Officer | A-Award | A | Performance Stock Units | 800,336 | 0.00 | — | 800,336 | D | ↗ |
| 2026-01-30 | Christian Waage | Director | A-Award | A | Common Stock | 53,960 | 0.00 | — | 53,960 | D | ↗ |
| 2026-01-19 | Forbes William P | Officer | M-Exempt | D | Restricted Stock Units | 3,875 | 0.00 | — | 30,994 | D | ↗ |
| 2026-01-19 | Duarte Ira | Officer | M-Exempt | A | Common Stock | 3,875 | 0.00 | — | 183,661 | D | ↗ |
| 2026-01-19 | Collard Craig A | Director / Officer | M-Exempt | D | Restricted Stock Units | 13,797 | 0.00 | — | 110,375 | D | ↗ |
| 2025-11-08 | Cusack Thomas | Director | A-Award | A | Stock Option (Right to Buy) | 227,272 | 1.10 | 250.0K | 227,272 | D | ↗ |
| 2025-10-31 | Forbes William P | Officer | M-Exempt | A | Common Stock | 11,694 | 0.00 | — | 166,203 | D | ↗ |
| 2025-10-31 | Duarte Ira | Officer | M-Exempt | A | Common Stock | 11,694 | 0.00 | — | 179,786 | D | ↗ |
| 2025-10-31 | Collard Craig A | Director / Officer | M-Exempt | A | Common Stock | 34,789 | 0.00 | — | 523,124 | D | ↗ |
| 2025-10-27 | Cusack Thomas | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-10-19 | Forbes William P | Officer | M-Exempt | D | Restricted Stock Units | 3,874 | 0.00 | — | 34,869 | D | ↗ |
| 2025-10-19 | Duarte Ira | Officer | M-Exempt | A | Common Stock | 3,874 | 0.00 | — | 168,092 | D | ↗ |
| 2025-10-19 | Collard Craig A | Director / Officer | M-Exempt | D | Restricted Stock Units | 13,797 | 0.00 | — | 124,172 | D | ↗ |
| 2025-10-15 | Rubric Capital Management LP | 10% Owner | C-Conversion | A | Common Stock, par value $0.01 per share ("Common Stock") | 946,100 | 0.00 | — | 30,046,828 | I | ↗ |
| 2025-08-08 | Rubric Capital Management LP | 10% Owner | P-Purchase | A | Common Stock, par value $0.01 per share ("Common Stock") | 2,387,225 | 1.50 | 3.58M | 29,100,728 | I | ↗ |
| 2025-08-08 | Morgan Adam | Director | P-Purchase | A | Common Stock | 1,766,546 | 1.50 | 2.65M | 8,753,290 | I | ↗ |
| 2025-07-31 | Forbes William P | Officer | M-Exempt | A | Common Stock | 11,695 | 0.00 | — | 150,635 | D | ↗ |
| 2025-07-31 | Duarte Ira | Officer | M-Exempt | A | Common Stock | 11,695 | 0.00 | — | 164,218 | D | ↗ |
| 2025-07-31 | Collard Craig A | Director / Officer | M-Exempt | A | Common Stock | 34,789 | 0.00 | — | 474,538 | D | ↗ |
| 2025-07-19 | Forbes William P | Officer | M-Exempt | A | Common Stock | 3,874 | 0.00 | — | 138,940 | D | ↗ |
| 2025-07-19 | Duarte Ira | Officer | M-Exempt | A | Common Stock | 3,874 | 0.00 | — | 152,523 | D | ↗ |
| 2025-07-19 | Collard Craig A | Director / Officer | M-Exempt | A | Common Stock | 13,797 | 0.00 | — | 439,749 | D | ↗ |
| 2025-06-16 | Duarte Ira | Officer | M-Exempt | A | Common Stock | 12,500 | 0.00 | — | 148,649 | D | ↗ |
| 2025-06-06 | Forbes William P | Officer | M-Exempt | A | Common Stock | 12,500 | 0.00 | — | 135,066 | D | ↗ |
| 2025-05-06 | Hensley Mark Earl | Officer | A-Award | A | Restricted Stock Units | 500,000 | 0.00 | — | 500,000 | D | ↗ |
| 2025-04-30 | Forbes William P | Officer | M-Exempt | A | Common Stock | 11,694 | 0.00 | — | 122,566 | D | ↗ |
| 2025-04-30 | Duarte Ira | Officer | M-Exempt | A | Restricted Stock Units | 11,694 | 0.00 | — | 175,416 | D | ↗ |
| 2025-04-30 | Collard Craig A | Director / Officer | M-Exempt | D | Restricted Stock Units | 34,789 | 0.00 | — | 521,831 | D | ↗ |
| 2025-04-28 | Hensley Mark Earl | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-04-19 | Forbes William P | Officer | M-Exempt | A | Common Stock | 3,875 | 0.00 | — | 110,872 | D | ↗ |
| 2025-04-19 | Duarte Ira | Officer | M-Exempt | A | Common Stock | 3,875 | 0.00 | — | 124,455 | D | ↗ |
| 2025-04-19 | Collard Craig A | Director / Officer | M-Exempt | A | Common Stock | 13,796 | 0.00 | — | 391,163 | D | ↗ |
| 2025-04-03 | Collard Craig A | Director / Officer | M-Exempt | D | Restricted Stock Units | 62,500 | 0.00 | — | 125,000 | D | ↗ |
| 2025-01-31 | Rodriguez Susan | Director | A-Award | A | Stock Option (Right to Buy) | 35,900 | 1.70 | 61.0K | 35,900 | D | ↗ |
| 2025-01-31 | Morgan Adam | Director | A-Award | A | Stock Option (Right to Buy) | 35,900 | 1.70 | 61.0K | 35,900 | D | ↗ |
| 2025-01-31 | Kaseta Michael | Director | A-Award | A | Stock Option (Right to Buy) | 35,900 | 1.70 | 61.0K | 35,900 | D | ↗ |
| 2025-01-31 | Johnson Craig A | Director | A-Award | A | Stock Option (Right to Buy) | 35,900 | 1.70 | 61.0K | 35,900 | D | ↗ |
| 2025-01-31 | Forbes William P | Officer | A-Award | A | Restricted Stock Units | 187,110 | 0.00 | — | 187,110 | D | ↗ |
| 2025-01-31 | Duarte Ira | Officer | A-Award | A | Restricted Stock Units | 187,110 | 0.00 | — | 187,110 | D | ↗ |
| 2025-01-31 | Dissanaike Sharmila | Director | A-Award | A | Stock Option (Right to Buy) | 35,900 | 1.70 | 61.0K | 35,900 | D | ↗ |
| 2025-01-31 | Collard Craig A | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 1,113,240 | 1.70 | 1.89M | 1,113,240 | D | ↗ |
| 2025-01-31 | Christian Waage | Director | A-Award | A | Stock Option (Right to Buy) | 35,900 | 1.70 | 61.0K | 35,900 | D | ↗ |
| 2025-01-30 | Rodriguez Susan | Director | A-Award | A | Common Stock | 17,950 | 0.00 | — | 87,180 | D | ↗ |
| 2025-01-30 | Morgan Adam | Director | A-Award | A | Stock Option (Right to Buy) | 35,900 | 1.73 | 62.1K | 35,900 | D | ↗ |
| 2025-01-30 | Kaseta Michael | Director | A-Award | A | Stock Option (Right to Buy) | 35,900 | 1.73 | 62.1K | 35,900 | D | ↗ |
| 2025-01-30 | Johnson Craig A | Director | A-Award | A | Stock Option (Right to Buy) | 35,900 | 1.73 | 62.1K | 35,900 | D | ↗ |
| 2025-01-30 | Dissanaike Sharmila | Director | A-Award | A | Stock Option (Right to Buy) | 35,900 | 1.73 | 62.1K | 35,900 | D | ↗ |
| 2025-01-30 | Christian Waage | Director | A-Award | A | Stock Option (Right to Buy) | 35,900 | 1.73 | 62.1K | 35,900 | D | ↗ |
| 2025-01-19 | Forbes William P | Officer | M-Exempt | A | Common Stock | 3,874 | 0.00 | — | 106,997 | D | ↗ |
| 2025-01-19 | Duarte Ira | Officer | M-Exempt | A | Common Stock | 3,874 | 0.00 | — | 120,580 | D | ↗ |
| 2025-01-19 | Collard Craig A | Director / Officer | M-Exempt | A | Common Stock | 13,797 | 0.00 | — | 314,867 | D | ↗ |
| 2024-11-04 | Kaseta Michael | Director | A-Award | A | Stock Option (Right to Buy) | 227,272 | 1.78 | 404.5K | 227,272 | D | ↗ |
| 2024-10-19 | Forbes William P | Officer | M-Exempt | D | Restricted Stock Units | 3,874 | 0.00 | — | 50,366 | D | ↗ |
| 2024-10-19 | Duarte Ira | Officer | M-Exempt | D | Restricted Stock Units | 3,874 | 0.00 | — | 50,366 | D | ↗ |
| 2024-10-19 | Collard Craig A | Director / Officer | M-Exempt | D | Restricted Stock Units | 13,797 | 0.00 | — | 179,359 | D | ↗ |
| 2024-07-19 | Forbes William P | Officer | M-Exempt | A | Common Stock | 3,875 | 0.00 | — | 99,249 | — | ↗ |
| 2024-07-19 | Duarte Ira | Officer | M-Exempt | A | Common Stock | 3,875 | 0.00 | — | 104,127 | — | ↗ |
| 2024-07-19 | Collard Craig A | Director / Officer | M-Exempt | A | Common Stock | 13,797 | 0.00 | — | 276,590 | — | ↗ |
| 2024-06-16 | Duarte Ira | Officer | M-Exempt | A | Common Stock | 12,500 | 0.00 | — | 100,252 | — | ↗ |
| 2024-06-06 | Forbes William P | Officer | M-Exempt | D | Restricted Stock Units | 12,500 | 0.00 | — | 37,500 | — | ↗ |
| 2024-04-19 | Forbes William P | Officer | M-Exempt | A | Common Stock | 3,874 | 0.00 | — | 82,874 | — | ↗ |
| 2024-04-19 | Duarte Ira | Officer | M-Exempt | A | Common Stock | 3,874 | 0.00 | — | 88,874 | — | ↗ |
| 2024-04-19 | Collard Craig A | Director / Officer | M-Exempt | A | Common Stock | 13,797 | 0.00 | — | 262,793 | — | ↗ |
| 2024-04-03 | Collard Craig A | Director / Officer | M-Exempt | A | Common Stock | 62,500 | 0.00 | — | 248,996 | — | ↗ |
| 2024-01-19 | Rodriguez Susan | Director | A-Award | A | Common Stock | 13,948 | 0.00 | — | 69,230 | — | ↗ |
| 2024-01-19 | Peraza Lisa | Officer | A-Award | A | Restricted Stock Units | 6,846 | 0.00 | — | 6,846 | — | ↗ |
| 2024-01-19 | Morgan Adam | Director | A-Award | A | Stock Option (Right to Buy) | 83,685 | 2.09 | 174.9K | 83,685 | — | ↗ |
| 2024-01-19 | Johnson Craig A | Director | A-Award | A | Common Stock | 13,948 | 0.00 | — | 65,820 | — | ↗ |
| 2024-01-19 | Forbes William P | Officer | A-Award | A | Restricted Stock Units | 61,989 | 0.00 | — | 61,989 | — | ↗ |
| 2024-01-19 | Duarte Ira | Officer | A-Award | A | Restricted Stock Units | 61,989 | 0.00 | — | 61,989 | — | ↗ |
| 2024-01-19 | Dissanaike Sharmila | Director | A-Award | A | Stock Option (Right to Buy) | 83,685 | 2.09 | 174.9K | 83,685 | — | ↗ |
| 2024-01-19 | Collard Craig A | Director / Officer | A-Award | A | Restricted Stock Units | 220,750 | 0.00 | — | 220,750 | — | ↗ |
| 2024-01-19 | Christian Waage | Director | A-Award | A | Common Stock | 13,948 | 0.00 | — | 66,180 | — | ↗ |
| 2024-01-13 | Peraza Lisa | Officer | M-Exempt | D | Restricted Stock Units | 552 | 0.00 | — | 1,656 | — | ↗ |
| 2023-11-17 | Forbes William P | Officer | P-Purchase | A | Common Stock | 25,000 | 1.09 | 27.3K | 79,000 | — | ↗ |
| 2023-11-16 | Forbes William P | Officer | P-Purchase | A | Common Stock | 50,000 | 0.94 | 47.0K | 54,000 | — | ↗ |
| 2023-11-16 | Duarte Ira | Officer | P-Purchase | A | Common Stock | 85,000 | 0.89 | 75.6K | 85,000 | — | ↗ |
| 2023-11-16 | Collard Craig A | Director / Officer | P-Purchase | A | Common Stock | 150,000 | 0.92 | 138.0K | 186,496 | — | ↗ |
| 2023-10-13 | Peraza Lisa | Officer | M-Exempt | D | Restricted Stock Units | 1,932 | 0.00 | — | 7,964 | — | ↗ |
| 2023-08-22 | Collard Craig A | Director / Officer | F-InKind | D | Common Stock | 692 | 1.65 | 1.1K | 36,496 | — | ↗ |
| 2023-07-25 | Peraza Lisa | Officer | F-InKind | D | Common Stock | 14,743 | 1.51 | 22.3K | 53,198 | — | ↗ |
| 2023-07-21 | Rubric Capital Management LP | 10% Owner | — | I | Common Stock, par value $0.01 per share | 0 | 0.00 | — | 26,713,503 | — | ↗ |
| 2023-07-21 | Morgan Adam | Director | P-Purchase | A | Common Stock, par value $0.01 per share | 2,486,744 | 1.37 | 3.41M | 6,986,744 | — | ↗ |
| 2023-07-17 | Peraza Lisa | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 150,000 | 1.32 | 198.0K | 150,000 | — | ↗ |
| 2023-07-13 | Szekeres David Leslie | Officer | M-Exempt | D | Restricted Stock Units | 1,250 | 0.00 | — | 6,250 | — | ↗ |
| 2023-07-13 | Peraza Lisa | Officer | M-Exempt | D | Restricted Stock Units | 1,933 | 0.00 | — | 9,896 | — | ↗ |
| 2023-06-16 | Duarte Ira | Officer | — | D | Employee Performance Stock Option (Right to Buy) | 500,000 | 1.21 | 605.0K | 0 | — | ↗ |
| 2023-06-06 | Forbes William P | Officer | — | D | Common Stock | 0 | 0.00 | — | 4,000 | — | ↗ |
| 2023-05-22 | Collard Craig A | Director / Officer | F-InKind | D | Common Stock | 691 | 1.45 | 1.0K | 37,188 | — | ↗ |
| 2023-04-13 | Szekeres David Leslie | Officer | M-Exempt | D | Restricted Stock Units | 1,250 | 0.00 | — | 7,500 | — | ↗ |
| 2023-04-13 | Peraza Lisa | Officer | M-Exempt | A | Common Stock | 1,932 | 0.00 | — | 24,545 | — | ↗ |
| 2023-04-13 | POYHONEN JOHN | Officer | M-Exempt | D | Restricted Stock Units | 1,250 | 0.00 | — | 7,500 | — | ↗ |
| 2023-04-13 | MANHARD KIMBERLY | Officer | M-Exempt | D | Restricted Stock Units | 1,250 | 0.00 | — | 7,500 | — | ↗ |
| 2023-04-03 | Collard Craig A | Director / Officer | A-Award | A | Employee Performance Stock Option (Right to Buy) | 4,250,000 | 1.78 | 7.57M | 4,250,000 | — | ↗ |
| 2023-02-22 | Morgan Adam | Director | A-Award | A | Common Stock | 37,879 | 0.00 | — | 37,879 | — | ↗ |
| 2023-02-22 | KOTLER KEVIN | Director | — | D | Stock Option (Right to Buy) | 227,272 | 2.70 | 613.6K | 0 | — | ↗ |
| 2023-02-22 | Collard Craig A | Director | — | D | Common Stock | 0 | 0.00 | — | 37,879 | — | ↗ |
| 2023-01-30 | Velan Capital Investment Management LP | — | — | I | Common Stock, par value $0.01 per share | 0 | 0.00 | — | 4,500,000 | — | ↗ |
| 2023-01-30 | Rubric Capital Management LP | — | — | I | Common Stock, par value $0.01 per share | 0 | 0.00 | — | 11,750,000 | — | ↗ |
| 2023-01-18 | Szekeres David Leslie | Officer | A-Award | A | Performance Stock Units | 49,788 | 0.00 | — | 49,788 | — | ↗ |
| 2023-01-18 | Quart Barry D | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 850,000 | 0.00 | — | 850,000 | — | ↗ |
| 2023-01-18 | Peraza Lisa | Officer | A-Award | A | Performance Stock Units | 42,631 | 0.00 | — | 42,631 | — | ↗ |
| 2023-01-18 | POYHONEN JOHN | Officer | A-Award | A | Performance Stock Units | 66,385 | 0.00 | — | 66,385 | — | ↗ |
| 2023-01-18 | MANHARD KIMBERLY | Officer | A-Award | A | Performance Stock Units | 149,365 | 0.00 | — | 149,365 | — | ↗ |
| 2023-01-13 | Szekeres David Leslie | Officer | M-Exempt | D | Restricted Stock Units | 4,564 | 0.00 | — | 32,500 | — | ↗ |
| 2023-01-13 | Quart Barry D | Officer | M-Exempt | A | Common Stock | 16,122 | 0.00 | — | 183,208 | — | ↗ |
| 2023-01-13 | Peraza Lisa | Officer | M-Exempt | D | Restricted Stock Units | 552 | 0.00 | — | 3,864 | — | ↗ |
| 2023-01-13 | POYHONEN JOHN | Officer | M-Exempt | D | Restricted Stock Units | 4,564 | 0.00 | — | 32,500 | — | ↗ |
| 2023-01-13 | MANHARD KIMBERLY | Officer | M-Exempt | D | Restricted Stock Units | 1,250 | 0.00 | — | 8,750 | — | ↗ |
| 2022-12-16 | Rodriguez Susan | Director | A-Award | A | Common Stock | 38,580 | 0.00 | — | 55,282 | — | ↗ |
| 2022-12-16 | Johnson Craig A | Director | A-Award | A | Common Stock | 38,580 | 0.00 | — | 51,872 | — | ↗ |
| 2022-12-16 | Dissanaike Sharmila | Director | A-Award | A | Common Stock | 38,580 | 0.00 | — | 55,282 | — | ↗ |
| 2022-12-16 | DAVIS STEPHEN | Director | A-Award | A | Stock Option (Right to Buy) | 77,160 | 0.00 | — | 77,160 | — | ↗ |
| 2022-12-16 | Christian Waage | Director | A-Award | A | Stock Option (Right to Buy) | 77,160 | 0.00 | — | 77,160 | — | ↗ |
| 2022-10-31 | Szekeres David Leslie | Officer | J-Other | A | Common Stock | 1,654 | 3.27 | 5.4K | 22,348 | — | ↗ |
| 2022-10-31 | Quart Barry D | Officer | J-Other | A | Common Stock | 1,655 | 3.27 | 5.4K | 163,441 | — | ↗ |
| 2022-10-31 | MANHARD KIMBERLY | Officer | J-Other | A | Common Stock | 1,655 | 3.27 | 5.4K | 20,131 | — | ↗ |
| 2022-10-13 | Szekeres David Leslie | Officer | M-Exempt | D | Restricted Stock Units | 1,250 | 0.00 | — | 10,000 | — | ↗ |
| 2022-10-13 | Quart Barry D | Officer | M-Exempt | D | Restricted Stock Units | 3,646 | 0.00 | — | 29,166 | — | ↗ |
| 2022-10-13 | Peraza Lisa | Officer | M-Exempt | D | Restricted Stock Units | 553 | 0.00 | — | 4,416 | — | ↗ |
| 2022-10-13 | POYHONEN JOHN | Officer | M-Exempt | D | Restricted Stock Units | 1,250 | 0.00 | — | 10,000 | — | ↗ |
| 2022-10-13 | MANHARD KIMBERLY | Officer | F-InKind | D | Common Stock | 2,012 | 3.76 | 7.6K | 18,476 | — | ↗ |
| 2022-07-25 | Szekeres David Leslie | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 165,961 | 0.00 | — | 165,961 | — | ↗ |
| 2022-07-25 | Peraza Lisa | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 60,902 | 3.17 | 193.1K | 60,902 | — | ↗ |
| 2022-07-25 | POYHONEN JOHN | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 165,961 | 0.00 | — | 165,961 | — | ↗ |
| 2022-07-25 | MANHARD KIMBERLY | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 165,961 | 3.17 | 526.1K | 165,961 | — | ↗ |
| 2022-07-13 | Szekeres David Leslie | Officer | J-Other | A | Common Stock | 1,505 | 3.84 | 5.8K | 13,090 | — | ↗ |
| 2022-07-13 | Quart Barry D | Officer | M-Exempt | D | Restricted Stock Units | 3,646 | 0.00 | — | 32,812 | — | ↗ |
| 2022-07-13 | Peraza Lisa | Officer | M-Exempt | D | Restricted Stock Units | 552 | 0.00 | — | 4,969 | — | ↗ |
| 2022-07-13 | POYHONEN JOHN | Officer | M-Exempt | A | Common Stock | 1,250 | 0.00 | — | 32,690 | — | ↗ |
| 2022-07-13 | MANHARD KIMBERLY | Director / Officer | M-Exempt | A | Common Stock | 1,250 | 0.00 | — | 12,122 | — | ↗ |
| 2022-05-03 | MANHARD KIMBERLY | Officer | S-Sale | D | Common Stock | 1,504 | 4.76 | 7.2K | 10,872 | — | ↗ |
| 2022-04-13 | Szekeres David Leslie | Officer | F-InKind | D | Common Stock | 2,012 | 6.07 | 12.2K | 11,585 | — | ↗ |
| 2022-04-13 | Quart Barry D | Director / Officer | M-Exempt | D | Restricted Stock Units | 3,646 | 0.00 | — | 36,458 | — | ↗ |
| 2022-04-13 | Peraza Lisa | Officer | M-Exempt | D | Restricted Stock Units | 552 | 0.00 | — | 5,521 | — | ↗ |
| 2022-04-13 | POYHONEN JOHN | Officer | M-Exempt | A | Common Stock | 1,250 | 0.00 | — | 28,888 | — | ↗ |
| 2022-04-13 | MANHARD KIMBERLY | Officer | F-InKind | D | Common Stock | 2,012 | 6.07 | 12.2K | 10,872 | — | ↗ |
| 2022-01-13 | Szekeres David Leslie | Officer | M-Exempt | A | Common Stock | 1,250 | 0.00 | — | 5,231 | — | ↗ |
| 2022-01-13 | Quart Barry D | Director / Officer | M-Exempt | D | Restricted Stock Units | 16,122 | 0.00 | — | 179,295 | — | ↗ |
| 2022-01-13 | Peraza Lisa | Officer | M-Exempt | A | Common Stock | 552 | 0.00 | — | 14,749 | — | ↗ |
| 2022-01-13 | POYHONEN JOHN | Officer | M-Exempt | D | Restricted Stock Units | 1,250 | 0.00 | — | 13,750 | — | ↗ |
| 2022-01-13 | MANHARD KIMBERLY | Director / Officer | M-Exempt | A | Common Stock | 1,250 | 0.00 | — | 4,518 | — | ↗ |
| 2021-12-22 | Rodriguez Susan | Director | A-Award | A | Common Stock | 10,452 | 0.00 | — | 16,702 | — | ↗ |
| 2021-12-22 | Johnson Craig A | Director | A-Award | A | Common Stock | 10,452 | 0.00 | — | 13,292 | — | ↗ |
| 2021-12-22 | Dissanaike Sharmila | Director | A-Award | A | Common Stock | 10,452 | 0.00 | — | 16,702 | — | ↗ |
| 2021-12-22 | DAVIS STEPHEN | Director | A-Award | A | Common Stock | 10,452 | 0.00 | — | 13,452 | — | ↗ |
| 2021-12-22 | Christian Waage | Director | A-Award | A | Common Stock | 10,452 | 0.00 | — | 13,652 | — | ↗ |
| 2021-12-21 | Johnson Craig A | Director | S-Sale | D | Common Stock | 250 | 9.73 | 2.4K | 2,840 | — | ↗ |
| 2021-12-21 | Christian Waage | Director | S-Sale | D | Common Stock | 300 | 9.73 | 2.9K | 3,200 | — | ↗ |
| 2021-10-29 | POYHONEN JOHN | Officer | J-Other | A | Common Stock | 817 | 9.36 | 7.6K | 23,836 | — | ↗ |
| 2021-10-13 | Szekeres David Leslie | Officer | F-InKind | D | Common Stock | 433 | 10.55 | 4.6K | 3,981 | — | ↗ |
| 2021-10-13 | Quart Barry D | Director / Officer | M-Exempt | D | Restricted Stock Units | 3,646 | 0.00 | — | 43,750 | — | ↗ |
| 2021-10-13 | Peraza Lisa | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 13,013 | 10.55 | 137.3K | 13,013 | — | ↗ |
| 2021-10-13 | POYHONEN JOHN | Officer | M-Exempt | D | Restricted Stock Units | 1,250 | 0.00 | — | 15,000 | — | ↗ |
| 2021-10-13 | MANHARD KIMBERLY | Director / Officer | A-Award | A | Restricted Stock Units | 55,320 | 0.00 | — | 55,320 | — | ↗ |
| 2021-09-21 | Johnson Craig A | Director | S-Sale | D | Common Stock | 250 | 12.30 | 3.1K | 3,090 | — | ↗ |
| 2021-09-21 | Christian Waage | Director | S-Sale | D | Common Stock | 300 | 12.31 | 3.7K | 3,500 | — | ↗ |
| 2021-09-20 | Rodriguez Susan | Director | — | D | Stock Option (Right to Buy) | 37,500 | 12.15 | 455.6K | 0 | — | ↗ |
| 2021-09-20 | Dissanaike Sharmila | Director | — | D | Stock Option (Right to Buy) | 37,500 | 12.15 | 455.6K | 0 | — | ↗ |
| 2021-07-13 | Szekeres David Leslie | Officer | F-InKind | D | Common Stock | 433 | 13.48 | 5.8K | 3,164 | — | ↗ |
| 2021-07-13 | Quart Barry D | Director / Officer | M-Exempt | D | Restricted Stock Units | 3,645 | 0.00 | — | 47,396 | — | ↗ |
| 2021-07-13 | Peraza Lisa | Officer | F-InKind | D | Common Stock | 191 | 13.48 | 2.6K | 13,836 | — | ↗ |
| 2021-07-13 | POYHONEN JOHN | Officer | M-Exempt | D | Restricted Stock Units | 1,250 | 0.00 | — | 16,250 | — | ↗ |
| 2021-07-13 | MANHARD KIMBERLY | Director / Officer | M-Exempt | A | Common Stock | 1,250 | 0.00 | — | 2,884 | — | ↗ |
| 2021-06-21 | Johnson Craig A | Director | S-Sale | D | Common Stock | 250 | 15.20 | 3.8K | 3,340 | — | ↗ |
| 2021-06-21 | Christian Waage | Director | S-Sale | D | Common Stock | 300 | 15.20 | 4.6K | 3,800 | — | ↗ |
| 2021-05-03 | MANHARD KIMBERLY | Director / Officer | S-Sale | D | Common Stock | 1,529 | 17.66 | 27.0K | 1,634 | — | ↗ |
| 2021-04-30 | Szekeres David Leslie | Officer | J-Other | A | Common Stock | 1,530 | 13.90 | 21.3K | 2,347 | — | ↗ |
| 2021-04-30 | Quart Barry D | Director / Officer | J-Other | A | Common Stock | 1,529 | 13.90 | 21.2K | 96,721 | — | ↗ |
| 2021-04-30 | Peraza Lisa | Officer | J-Other | A | Common Stock | 1,530 | 13.90 | 21.3K | 13,475 | — | ↗ |
| 2021-04-30 | POYHONEN JOHN | Officer | J-Other | A | Common Stock | 971 | 13.90 | 13.5K | 21,385 | — | ↗ |
| 2021-04-30 | MANHARD KIMBERLY | Director / Officer | J-Other | A | Common Stock | 1,529 | 13.90 | 21.2K | 3,163 | — | ↗ |
| 2021-04-15 | Christian Waage | Director | S-Sale | D | Common Stock | 300 | 17.51 | 5.3K | 4,100 | — | ↗ |
| 2021-04-13 | Szekeres David Leslie | Officer | F-InKind | D | Common Stock | 433 | 16.66 | 7.2K | 817 | — | ↗ |
| 2021-04-13 | Quart Barry D | Director / Officer | M-Exempt | D | Restricted Stock Units | 3,646 | 0.00 | — | 51,041 | — | ↗ |
| 2021-04-13 | Peraza Lisa | Officer | M-Exempt | D | Restricted Stock Units | 552 | 0.00 | — | 7,729 | — | ↗ |
| 2021-04-13 | POYHONEN JOHN | Officer | F-InKind | D | Common Stock | 433 | 16.66 | 7.2K | 20,414 | — | ↗ |
| 2021-04-13 | MANHARD KIMBERLY | Director / Officer | F-InKind | D | Common Stock | 433 | 16.66 | 7.2K | 1,634 | — | ↗ |
| 2021-04-06 | Johnson Craig A | Director | S-Sale | D | Common Stock | 250 | 17.22 | 4.3K | 3,590 | — | ↗ |
| 2021-01-14 | Szekeres David Leslie | Officer | S-Sale | D | Common Stock | 827 | 18.09 | 15.0K | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-165.5K
Shares Outstanding
157.94M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Mark Hensley EVP, Chief Operating Officer | 372.2K | — | 1.21M | 2.53M | 187.1K | 10.5K | 4.31M | 86.77% | ↗ |
| 2 | 2025 | Craig Collard , Chief Executive Officer | 689.4K | — | 946.3K | 1.35M | 517.2K | 10.5K | 3.52M | 65.39% | ↗ |
| 3 | 2025 | William Forbes EVP, Chief Development Officer | 609.9K | — | 318.1K | 454.8K | 305.0K | — | 1.69M | 45.79% | ↗ |
| 4 | 2025 | Ira Duarte EVP, Chief Financial Officer | 559.8K | — | 318.1K | 454.8K | 287.5K | 10.5K | 1.63M | 47.40% | ↗ |
| 5 | 2024 | Craig Collard , Chief Executive Officer | 669.5K | — | 461.4K | 1.69M | 577.4K | — | 3.40M | 63.28% | ↗ |
| 6 | 2024 | William Forbes EVP, Chief Development Officer | 592.3K | — | 129.6K | 473.8K | 340.5K | — | 1.54M | 39.28% | ↗ |
| 7 | 2024 | Ira Duarte EVP, Chief Financial Officer | 515.0K | — | 129.6K | 473.8K | 296.1K | 10.4K | 1.42M | 42.34% | ↗ |
| 8 | 2023 | Craig Collard , Chief Executive Officer | 493.0K | — | 547.3K | 9.26M | 327.0K | 151.6K | 10.78M | 90.98% | ↗ |
| 9 | 2023 | Barry Quart, Pharm.D. , Former Chief Executive Officer | 188.5K | — | 788.6K | 1.63M | — | 1.43M | 4.03M | 59.90% | ↗ |
| 10 | 2023 | Ira Duarte EVP, Chief Financial Officer | 271.2K | — | 60.5K | 1.07M | 128.8K | 7.5K | 1.53M | 73.45% | ↗ |
| 11 | 2023 | Ira Duarte Chief Financial Officer | 271.2K | — | 60.5K | 1.07M | 128.8K | 7.5K | 1.53M | 73.45% | ↗ |
| 12 | 2023 | William Forbes EVP, Chief Development Officer | 329.5K | — | 55.5K | 917.4K | 155.7K | — | 1.46M | 66.73% | ↗ |
| 13 | 2023 | William Forbes Chief Development Officer | 329.5K | — | 55.5K | 917.4K | 155.7K | — | 1.46M | 66.73% | ↗ |
| 14 | 2023 | David Szekeres , Executive Vice President, Chief Commercial Officer | 305.5K | — | 400.9K | — | — | 1.17M | 877.4K | 45.70% | ↗ |
| 15 | 2022 | Kimberly Manhard Executive Vice President, Drug Development | 545.8K | — | 441.5K | 235.5K | 204.7K | 19.6K | 1.45M | 46.78% | ↗ |
| 16 | 2022 | David Szekeres , Executive Vice President, Chief Commercial Officer | 533.0K | — | 441.5K | 235.5K | 199.9K | 19.4K | 1.43M | 47.36% | ↗ |
| 17 | 2022 | David Szekeres Executive Vice President, Chief Commercial Officer | 533.0K | — | 441.5K | 235.5K | 199.9K | 19.4K | 1.43M | 47.36% | ↗ |
| 18 | 2022 | Barry Quart, Pharm.D. , Former Chief Executive Officer | 736.0K | — | — | — | 386.4K | 23.3K | 1.15M | 0.00% | ↗ |
| 19 | 2022 | Barry Quart, Pharm.D. Former Chief Executive Officer | 736.0K | — | — | — | 386.4K | 23.3K | 1.15M | 0.00% | ↗ |
| 20 | 2021 | Barry Quart, Pharm.D. Chief Executive Officer | 700.0K | — | 2.06M | 2.27M | 392.0K | 8.7K | 5.43M | 79.73% | ↗ |
| 21 | 2021 | Barry Quart, Pharm.D. Former Chief Executive Officer | 700.0K | — | 2.06M | 2.27M | 392.0K | 8.7K | 5.43M | 79.73% | ↗ |
| 22 | 2021 | Kimberly Manhard Executive Vice President, Drug Development | 514.9K | — | 583.6K | 535.1K | 206.0K | 18.9K | 1.86M | 60.20% | ↗ |
| 23 | 2021 | John Poyhonen President and Chief Commercial Officer | 509.7K | — | 583.6K | 535.1K | 203.9K | 8.7K | 1.84M | 60.77% | ↗ |
| 24 | 2021 | David Szekeres Executive Vice President, Chief Commercial Officer | 494.4K | — | 583.6K | 535.1K | 197.8K | 18.5K | 1.83M | 61.15% | ↗ |
| 25 | 2021 | David Szekeres Executive Vice President, Chief Operating Officer | 494.4K | — | 583.6K | 535.1K | 197.8K | 18.5K | 1.83M | 61.15% | ↗ |
| 26 | 2021 | Lisa Peraza Vice President, Chief Accounting Officer | 339.9K | — | 247.1K | 75.5K | 119.0K | 15.2K | 796.8K | 40.50% | ↗ |
| 27 | 2020 | Barry Quart, Pharm.D. Chief Executive Officer | 676.8K | — | 917.0K | 3.37M | 365.0K | 21.1K | 5.35M | 80.12% | ↗ |
| 28 | 2020 | John Poyhonen President and Chief Commercial Officer | 513.9K | — | 314.4K | 1.64M | 198.0K | 8.6K | 2.67M | 73.02% | ↗ |
| 29 | 2020 | David Szekeres Executive Vice President, Chief Operating Officer | 476.9K | — | 314.4K | 1.50M | 161.7K | 8.6K | 2.46M | 73.72% | ↗ |
| 30 | 2020 | Kimberly Manhard Executive Vice President, Drug Development | 519.2K | — | 314.4K | 1.15M | 200.0K | 8.6K | 2.20M | 66.87% | ↗ |
| 31 | 2020 | Lisa Peraza Vice President, Chief Accounting Officer | 328.8K | — | 138.9K | 990.8K | 105.7K | 14.6K | 1.58M | 71.56% | ↗ |
| 32 | 2020 | Robert Hoffman Former Chief Financial Officer and Senior Vice President, Finance | 360.0K | — | — | — | — | 668.3K | 1.03M | 0.00% | ↗ |
| 33 | 2019 | Barry Quart, Pharm.D. Chief Executive Officer | 639.0K | — | — | 4.92M | 306.7K | 8.4K | 5.87M | 83.75% | ↗ |
| 34 | 2019 | Barry Quart, Pharm.D. President and Chief Executive Officer | 639.0K | — | — | 4.92M | 306.7K | 8.4K | 5.87M | 83.75% | ↗ |
| 35 | 2019 | John Poyhonen President and Chief Commercial Officer | 216.7K | — | — | 4.21M | 90.8K | 6.2K | 4.52M | 93.07% | ↗ |
| 36 | 2019 | John Poyhonen Executive Vice President, Chief Commercial Officer | 216.7K | — | — | 4.21M | 90.8K | 6.2K | 4.52M | 93.07% | ↗ |
| 37 | 2019 | Kimberly Manhard Executive Vice President, Drug Development | 490.1K | — | — | 1.82M | 196.1K | 8.4K | 2.51M | 72.33% | ↗ |
| 38 | 2019 | Robert Hoffman Chief Financial Officer and Senior Vice President, Finance | 388.7K | — | — | 1.51M | 124.4K | 8.4K | 2.03M | 74.36% | ↗ |
| 39 | 2019 | Robert Hoffman Former Chief Financial Officer and Senior Vice President, Finance | 388.7K | — | — | 1.51M | 124.4K | 8.4K | 2.03M | 74.36% | ↗ |
| 40 | 2019 | Robert Rosen Former President | 78.6K | — | — | — | — | 1.02M | 1.10M | 0.00% | ↗ |
| 41 | 2018 | Barry Quart, Pharm.D. President and Chief Executive Officer | 614.4K | — | — | 4.82M | 553.0K | 8.3K | 5.99M | 80.38% | ↗ |
| 42 | 2018 | Barry Quart, Pharm.D. Chief Executive Officer | 614.4K | — | — | 4.82M | 553.0K | 8.3K | 5.99M | 80.38% | ↗ |
| 43 | 2018 | Barry Quart, Pharm.D. Current President and Chief Executive Officer | 614.4K | — | — | 4.82M | 553.0K | 8.3K | 5.99M | 80.38% | ↗ |
| 44 | 2018 | Robert Rosen Former President | 614.4K | — | — | 4.82M | 553.0K | — | 5.98M | 80.49% | ↗ |
| 45 | 2018 | Kimberly Manhard Executive Vice President, Drug Development | 466.8K | — | — | 1.61M | 350.1K | 8.3K | 2.43M | 66.05% | ↗ |
| 46 | 2018 | Kimberly Manhard Executive Vice President Drug Development | 466.8K | — | — | 1.61M | 350.1K | 8.3K | 2.43M | 66.05% | ↗ |
| 47 | 2018 | Robert Hoffman Former Chief Financial Officer and Senior Vice President, Finance | 357.4K | — | — | 1.14M | 214.5K | 8.0K | 1.72M | 66.28% | ↗ |
| 48 | 2018 | Robert Hoffman Chief Financial Officer and Senior Vice President, Finance | 357.4K | — | — | 1.14M | 214.5K | 8.0K | 1.72M | 66.28% | ↗ |
| 49 | 2018 | Robert Hoffman Chief Financial Officer and Senior Vice President, Finance Former Executive Officer: | 357.4K | — | — | 1.14M | 214.5K | 8.0K | 1.72M | 66.28% | ↗ |
| 50 | 2017 | Barry Quart, Pharm.D. Current President and Chief Executive Officer | 596.5K | — | — | 3.39M | 247.0K | 8.1K | 4.24M | 79.93% | ↗ |
| 51 | 2017 | Barry Quart, Pharm.D. President and Chief Executive Officer | 596.5K | — | — | 3.39M | 247.0K | 8.1K | 4.24M | 79.93% | ↗ |
| 52 | 2017 | Barry D. Quart, Pharm.D. Chief Executive Officer | 596.5K | — | — | 3.39M | 247.0K | 8.1K | 4.24M | 79.93% | ↗ |
| 53 | 2017 | Robert Rosen Former President | 596.5K | — | — | 3.39M | 247.0K | — | 4.24M | 80.08% | ↗ |
| 54 | 2017 | Robert H. Rosen President | 596.5K | — | — | 3.39M | 247.0K | — | 4.24M | 80.08% | ↗ |
| 55 | 2017 | Robert Hoffman Chief Financial Officer and Senior Vice President, Finance Former Executive Officer: | 235.6K | — | — | 1.97M | 68.4K | 3.6K | 2.28M | 86.51% | ↗ |
| 56 | 2017 | Robert Hoffman Chief Financial Officer and Senior Vice President, Finance | 235.6K | — | — | 1.97M | 68.4K | 3.6K | 2.28M | 86.51% | ↗ |
| 57 | 2017 | Robert E. Hoffman Chief Financial Officer and Senior Vice President, Finance Former Executive Officers: | 235.6K | — | — | 1.97M | 68.4K | 3.6K | 2.28M | 86.51% | ↗ |
| 58 | 2017 | Kimberly Manhard Executive Vice President, Drug Development | 453.2K | — | — | 1.31M | 156.4K | 8.1K | 1.93M | 68.01% | ↗ |
| 59 | 2017 | Kimberly Manhard Executive Vice President Drug Development | 453.2K | — | — | 1.31M | 156.4K | 8.1K | 1.93M | 68.01% | ↗ |
| 60 | 2017 | Kimberly J. Manhard Executive Vice President Drug Development | 453.2K | — | — | 1.31M | 156.4K | 8.1K | 1.93M | 68.01% | ↗ |
| 61 | 2017 | Brian G. Drazba Vice President, Finance and Chief Financial Officer | 91.3K | — | — | — | 33.9K | 441.4K | 566.7K | 0.00% | ↗ |
| 62 | 2016 | Kimberly Manhard Executive Vice President Drug Development | 401.1K | — | — | 5.80M | 132.0K | 8.0K | 6.34M | 91.47% | ↗ |
| 63 | 2016 | Kimberly J. Manhard Executive Vice President, Drug Development Former Executive Officers: | 401.1K | — | — | 5.80M | 132.0K | 8.0K | 6.34M | 91.47% | ↗ |
| 64 | 2016 | Kimberly J. Manhard Executive Vice President Drug Development | 401.1K | — | — | 5.80M | 132.0K | 8.0K | 6.34M | 91.47% | ↗ |
| 65 | 2016 | Barry D. Quart, Pharm.D. Chief Executive Officer | 579.1K | — | — | 2.98M | 208.5K | 8.0K | 3.77M | 78.91% | ↗ |
| 66 | 2016 | Barry Quart, Pharm.D. Current President and Chief Executive Officer | 579.1K | — | — | 2.98M | 208.5K | 8.0K | 3.77M | 78.91% | ↗ |
| 67 | 2016 | Robert Rosen Former President | 579.1K | — | — | 2.98M | 208.5K | — | 3.76M | 79.08% | ↗ |
| 68 | 2016 | Robert H. Rosen President | 579.1K | — | — | 2.98M | 208.5K | — | 3.76M | 79.08% | ↗ |
| 69 | 2016 | Paul G. Marshall Senior Vice President, Technical Operations | 319.8K | — | — | — | — | 590.1K | 909.9K | 0.00% | ↗ |
| 70 | 2016 | Brian G. Drazba Vice President, Finance and Chief Financial Officer | 339.2K | — | — | — | 108.6K | 8.0K | 455.7K | 0.00% | ↗ |
| 71 | 2015 | Barry D. Quart, Pharm.D. Chief Executive Officer | 551.6K | — | — | 5.58M | 333.7K | 8.0K | 6.48M | 86.21% | ↗ |
| 72 | 2015 | Robert H. Rosen President and Chief Commercial Officer | 551.6K | — | — | 5.58M | 333.7K | — | 6.47M | 86.31% | ↗ |
| 73 | 2015 | Robert H. Rosen President | 551.6K | — | — | 5.58M | 333.7K | — | 6.47M | 86.31% | ↗ |
| 74 | 2015 | Neil J. Clendeninn, M.D., Ph.D. Senior Vice President and Chief Medical Officer | 84.6K | — | — | 3.24M | — | — | 3.32M | 97.45% | ↗ |
| 75 | 2015 | Paul G. Marshall Senior Vice President, Technical Operations | 402.9K | — | — | 1.12M | 177.3K | 8.0K | 1.70M | 65.50% | ↗ |
| 76 | 2015 | Brian G. Drazba Vice President, Finance and Chief Financial Officer | 310.7K | — | — | 1.12M | 97.9K | 8.0K | 1.53M | 72.83% | ↗ |
| 77 | 2014 | Robert H. Rosen President and Chief Commercial Officer | 540.8K | — | — | 3.33M | 252.8K | — | 4.12M | 80.74% | ↗ |
| 78 | 2014 | Robert H. Rosen President and Chief Commercial Officer | 540.8K | — | — | 3.33M | 252.8K | — | 4.12M | 80.74% | ↗ |
| 79 | 2014 | Robert H. Rosen President | 540.8K | — | — | 3.33M | 252.8K | — | 4.12M | 80.74% | ↗ |
| 80 | 2014 | Barry D. Quart, Pharm.D. Chief Executive Officer | 540.8K | — | — | 3.08M | 252.8K | 7.8K | 3.88M | 79.37% | ↗ |
| 81 | 2014 | Barry D. Quart, Pharm.D. Chief Executive Officer | 540.8K | — | — | 3.08M | 252.8K | 7.8K | 3.88M | 79.37% | ↗ |
| 82 | 2014 | Mark S. Gelder, M.D. Former Senior Vice President and Chief Medical Officer | 412.0K | — | — | 2.12M | 105.1K | 7.8K | 2.65M | 80.19% | ↗ |
| 83 | 2014 | Paul G. Marshall Senior Vice President, Technical Operations | 395.0K | — | — | 313.1K | 100.7K | 7.8K | 816.6K | 38.34% | ↗ |
| 84 | 2014 | Paul G. Marshall Senior Vice President, Technical Operations | 395.0K | — | — | 313.1K | 100.7K | 7.8K | 816.6K | 38.34% | ↗ |
| 85 | 2014 | Brian G. Drazba Vice President, Finance and Chief Financial Officer | 285.0K | — | — | 243.5K | 79.1K | — | 607.6K | 40.08% | ↗ |
| 86 | 2014 | Brian G. Drazba Vice President, Finance and Chief Financial Officer | 285.0K | — | — | 243.5K | 79.1K | — | 607.6K | 40.08% | ↗ |
| 87 | 2013 | Robert H. Rosen President and Chief Commercial Officer | 453.8K | — | — | 7.87M | 317.2K | — | 8.64M | 91.08% | ↗ |
| 88 | 2013 | Robert H. Rosen President and Chief Commercial Officer | 453.8K | — | — | 7.87M | 317.2K | — | 8.64M | 91.08% | ↗ |
| 89 | 2013 | Robert H. Rosen President | 453.8K | — | — | 7.87M | 317.2K | — | 8.64M | 91.08% | ↗ |
| 90 | 2013 | Barry D. Quart, Pharm.D. Chief Executive Officer | 349.3K | — | — | 7.63M | 240.6K | 41.0K | 8.26M | 92.36% | ↗ |
| 91 | 2013 | Barry D. Quart, Pharm.D. Chief Executive Officer | 349.3K | — | — | 7.63M | 240.6K | 41.0K | 8.26M | 92.36% | ↗ |
| 92 | 2013 | Stephen R. Davis Executive Vice President and Chief Operating Officer | 266.2K | — | — | 3.73M | 133.3K | 35.0K | 4.16M | 89.56% | ↗ |
| 93 | 2013 | Paul G. Marshall Senior Vice President, Technical Operations | 62.3K | — | — | 2.28M | 26.3K | — | 2.37M | 96.26% | ↗ |
| 94 | 2013 | Paul G. Marshall Senior Vice President, Technical Operations | 62.3K | — | — | 2.28M | 26.3K | — | 2.37M | 96.26% | ↗ |
| 95 | 2013 | John B. Whelan Former President and Chief Executive Officer; Former | 255.6K | — | — | 1.23M | — | 522.7K | 2.01M | 61.32% | ↗ |
| 96 | 2013 | Mark S. Gelder, M.D. Former Senior Vice President and Chief Medical Officer | 361.5K | — | — | 731.0K | 162.5K | 7.7K | 1.26M | 57.89% | ↗ |
| 97 | 2013 | Mark S. Gelder, M.D. Senior Vice President and Chief Medical Officer | 361.5K | — | — | 730.7K | 162.5K | 7.7K | 1.26M | 57.88% | ↗ |
| 98 | 2013 | Brian G. Drazba Vice President, Finance and Chief Financial Officer | 52.6K | — | — | 866.8K | 14.3K | — | 933.7K | 92.84% | ↗ |
| 99 | 2013 | Brian G. Drazba Vice President, Finance and Chief Financial Officer | 52.6K | — | — | 866.8K | 14.3K | — | 933.7K | 92.84% | ↗ |
| 100 | 2012 | Robert Rosen Former Senior Vice President and Chief Commercial Officer; current President | 65.6K | — | — | 5.73M | 15.1K | 5.0K | 5.82M | 98.53% | ↗ |
| 101 | 2012 | Robert H. Rosen President and Chief Commercial Officer | 65.6K | — | — | 5.73M | 15.1K | 5.0K | 5.82M | 98.53% | ↗ |
| 102 | 2012 | Robert H. Rosen President | 65.6K | — | — | 5.73M | 15.1K | 5.0K | 5.82M | 98.53% | ↗ |
| 103 | 2012 | Barry D. Quart, Pharm.D. Chief Executive Officer | — | — | — | 2.46M | — | 15.0K | 2.48M | 99.39% | ↗ |
| 104 | 2012 | Stephen R. Davis Executive Vice President and Chief Operating Officer | — | — | — | 2.46M | — | 15.0K | 2.48M | 99.39% | ↗ |
| 105 | 2012 | Mark S. Gelder, M.D. Senior Vice President and Chief Medical Officer | 26.9K | — | — | 1.70M | — | 40.0K | 1.76M | 96.21% | ↗ |
| 106 | 2012 | Mark S. Gelder, M.D. Former Senior Vice President and Chief Medical Officer | 26.9K | — | — | 1.70M | — | 40.0K | 1.76M | 96.21% | ↗ |
| 107 | 2012 | John B. Whelan Former President and Chief Executive Officer; Former | 395.0K | — | — | — | 128.4K | 7.5K | 530.9K | 0.00% | ↗ |
| 108 | 2012 | John B. Whelan Former President and Chief Executive Officer; current Chief Financial Officer | 395.0K | — | — | — | 128.4K | 7.5K | 530.8K | 0.00% | ↗ |
| 109 | 2012 | Michael Adam, Ph.D. Former Senior Vice President and Chief Operating Officer | 312.0K | — | — | — | 73.7K | 7.5K | 393.1K | 0.00% | ↗ |
| 110 | 2012 | Brian G. Drazba Vice President, Finance and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 111 | 2012 | Paul G. Marshall Senior Vice President, Technical Operations | — | — | — | — | — | — | — | — | ↗ |
| 112 | 2011 | John B. Whelan Former President and Chief Executive Officer; current Chief Financial Officer | 354.2K | — | — | 5.36M | 197.5K | 7.4K | 5.92M | 90.55% | ↗ |
| 113 | 2011 | John B. Whelan Former President and Chief Executive Officer; Former | 354.2K | — | — | 5.36M | 197.5K | 7.4K | 5.92M | 90.55% | ↗ |
| 114 | 2011 | John B. Whelan President, Chief Executive Officer and Chief Financial Officer | 354.2K | — | — | 5.36M | 197.5K | 7.4K | 5.92M | 90.55% | ↗ |
| 115 | 2011 | Michael Adam, Ph.D. Former Senior Vice President and Chief Operating Officer | 216.0K | — | — | 2.44M | 109.2K | 5.0K | 2.77M | 88.09% | ↗ |
| 116 | 2011 | Michael Adam, Ph.D. Sr. Vice President and Chief Operating Officer | 216.0K | — | — | 2.44M | 109.2K | 5.0K | 2.77M | 88.09% | ↗ |
| 117 | 2011 | John Barr, Ph.D. Sr. Vice President, Research and Development | 290.4K | — | — | 1.47M | 63.2K | 8.7K | 362.5K | 404.95% | ↗ |
| 118 | 2011 | Barry D. Quart, Pharm.D. Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 119 | 2011 | Stephen R. Davis Executive Vice President and Chief Operating Officer | — | — | — | — | — | — | — | — | ↗ |
| 120 | 2011 | Mark S. Gelder, M.D. Senior Vice President and Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 121 | 2011 | Brian G. Drazba Vice President, Finance and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 122 | 2011 | Robert H. Rosen President | — | — | — | — | — | — | — | — | ↗ |
| 123 | 2011 | Robert Rosen Former Senior Vice President and Chief Commercial Officer; current President | — | — | — | — | — | — | — | — | ↗ |
| 124 | 2010 | Ronald J. Prentki Former President and Chief Executive Officer | 191.3K | — | — | 462.6K | — | 880.4K | 1.53M | 30.15% | ↗ |
| 125 | 2010 | John Barr, Ph.D. Sr. Vice President, Research and Development | 302.0K | — | — | 363.8K | — | 17.1K | 682.8K | 53.27% | ↗ |
| 126 | 2010 | John Barr Sr. Vice President, Research and Development | 302.0K | — | — | 363.8K | — | 17.1K | 682.8K | 53.27% | ↗ |
| 127 | 2010 | John B. Whelan President, Chief Executive Officer and Chief Financial Officer | 300.0K | — | — | 363.8K | — | 7.4K | 671.1K | 54.20% | ↗ |
| 128 | 2010 | Michael Adam, Ph.D. Sr. Vice President and Chief Operating Officer | — | — | — | — | — | — | — | — | ↗ |
| 129 | 2009 | Ronald J. Prentki Former President and Chief Executive Officer | 441.3K | — | 56.8K | — | 72.0K | 7.4K | 577.5K | 9.83% | ↗ |
| 130 | 2009 | Ronald J. Prentki President and Chief Executive Officer | 441.3K | — | 56.8K | — | 72.0K | 7.4K | 577.5K | 9.83% | ↗ |
| 131 | 2009 | John B. Whelan Vice President, Chief Financial Officer | 259.6K | — | — | 211.1K | 40.0K | 6.9K | 517.6K | 40.78% | ↗ |
| 132 | 2009 | John B. Whelan President, Chief Executive Officer and Chief Financial Officer | 259.6K | — | — | 211.1K | 40.0K | 6.9K | 517.6K | 40.78% | ↗ |
| 133 | 2009 | John Barr Sr. Vice President, Research and Development | 313.6K | — | — | 112.3K | 47.3K | 15.5K | 488.6K | 22.98% | ↗ |
| 134 | 2008 | Ronald J. Prentki President and Chief Executive Officer | 196.2K | — | — | 1.65M | — | 2.9K | 1.85M | 89.21% | ↗ |
| 135 | 2008 | Gregory Turnbull Former President and Chief Executive Officer and Interim Chief Financial Officer | 347.2K | — | 12.5K | 245.3K | — | 31.5K | 636.5K | 40.50% | ↗ |
| 136 | 2008 | John Barr Sr. Vice President, Research and Development | 290.2K | — | — | 259.6K | 30.5K | 16.2K | 596.6K | 43.52% | ↗ |
| 137 | 2008 | Ronald Prentki | 196.2K | — | — | 199.5K | — | 2.9K | 398.6K | 50.05% | ↗ |
| 138 | 2008 | Anastassios Retzios Former Vice President, Clinical Research | 217.1K | — | — | 48.3K | — | 5.7K | 271.0K | 17.82% | ↗ |
| 139 | 2008 | John B. Whelan Vice President, Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 140 | 2007 | Gregory Turnbull President and Chief Executive Officer | 418.0K | — | 9.0K | 52.3K | — | 31.0K | 510.3K | 12.02% | ↗ |
| 141 | 2007 | Gregory Turnbull Former President and Chief Executive Officer and Interim Chief Financial Officer | 418.0K | — | 9.0K | 52.3K | — | 31.0K | 510.3K | 12.02% | ↗ |
| 142 | 2007 | John Barr Sr. Vice President, Research and Development | 262.2K | — | 10.6K | 32.9K | 55.1K | 17.0K | 377.7K | 11.52% | ↗ |
| 143 | 2007 | Michael O’Connell Former Chief Executive Officer, Chief Operating Officer and Chief Financial Officer | 227.6K | — | 21.2K | 34.8K | 47.8K | 18.4K | 349.8K | 16.01% | ↗ |
| 144 | 2007 | Anastassios Retzios Former Vice President, Clinical Research | 208.1K | — | — | 20.6K | 31.2K | 6.2K | 266.1K | 7.73% | ↗ |
| 145 | 2007 | Anastassios Retzios Vice President, Clinical Research | 208.1K | — | — | 20.6K | 31.2K | 6.2K | 266.1K | 7.73% | ↗ |
| 146 | 2006 | Michael O’Connell President and Chief Executive Officer | 345.3K | — | 21.1K | 53.8K | 24.8K | 17.4K | 462.3K | 16.19% | ↗ |
| 147 | 2006 | Michael O’Connell Former Chief Executive Officer, Chief Operating Officer and Chief Financial Officer | 345.3K | — | 21.1K | 53.8K | 24.8K | 17.4K | 462.3K | 16.19% | ↗ |
| 148 | 2006 | John Barr Vice President, Research and Development | 239.6K | — | 10.6K | 16.6K | 17.2K | 14.4K | 298.4K | 9.10% | ↗ |
| 149 | 2006 | John Barr Sr. Vice President, Research and Development | 239.6K | — | 10.6K | 16.6K | 17.2K | 14.4K | 298.4K | 9.10% | ↗ |
| 150 | 2006 | Gordon Sangster Former Chief Financial Officer and Vice President, Finance | 147.9K | — | — | 2.5K | — | 11.9K | 162.3K | 1.56% | ↗ |
| 151 | 2006 | Gregory Turnbull President and Chief Executive Officer | 38.1K | — | 5.1K | 48.3K | — | 30.6K | 122.1K | 43.75% | ↗ |
| 152 | 2006 | Gregory Turnbull President and Chief Executive Officer | 38.1K | — | 5.1K | 48.3K | — | 30.6K | 122.1K | 43.75% | ↗ |
| 153 | 2006 | Stephen Whiteford Chief Financial Officer and Vice President, Finance | 67.0K | — | 3.4K | — | — | 1.5K | 71.8K | 4.67% | ↗ |
| 154 | 2006 | Anastassios Retzios Vice President, Clinical Research | 19.7K | — | — | 2.3K | 30.0K | — | 52.0K | 4.44% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Craig Alexander Collard | Chief Executive Officer & Director | 1M | male |
| William Forbes D. | Executive Vice President & Chief Development Officer | 914.9K | — |
| Ira Duarte | Executive Vice President & Chief Financial Officer | 857.8K | female |
| Mark E. Hensley | Executive Vice President & Chief Operating Officer | 748.9K | male |
| Brett Fleshman | Chief Business Officer | — | male |
| Melissa Jarel | Executive Director of Legal | — | — |
| Robert Sullivan | Senior Vice President of Oncology Care Franchise & Commercial Operations | — | male |
| Ryan Craig | Vice President of Marketing | — | male |
| Kevin Warner | Senior Vice President of Medical Affairs Strategy & Engagement | — | — |
| Jeff Cohn | Executive Director, Assistant General Counsel & Assistant Secretary | — | male |
| John Aiken | Executive Director of People Management & Training | — | male |
| John C. Arthur | Senior Vice President of Manufacturing & Supply | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2021-03-31 | 2021-04-05 | Ashley Hinson Arenholz | IA01 | Self | Sale (Full) | $1,001 - $15,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for HRTX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
